<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cephalosporin hypersensitivity: Clinical manifestations and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cephalosporin hypersensitivity: Clinical manifestations and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cephalosporin hypersensitivity: Clinical manifestations and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Antonino Romano, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth J Phillips, MD, FRCPC, FRACP, FIDSA, FAAAAI</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 07, 2020.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2769649074"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cephalosporins are among the most commonly used antibiotics, and their use is increasing over time [<a href="#rid1">1-4</a>]. Several types of hypersensitivity reactions have been reported with cephalosporins, ranging from mild, delayed-onset cutaneous reactions to life-threatening anaphylaxis in patients with immunoglobulin E (IgE)-mediated allergy [<a href="#rid5">5-11</a>].</p><p>This topic reviews the clinical manifestations, pathogenesis, and diagnosis of hypersensitivity reactions to cephalosporins. Issues of cross-reactivity between cephalosporins, penicillins, and related drugs, and the subsequent use of cephalosporins and related antibiotics in patients with cephalosporin or penicillin allergy, are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/13536.html" rel="external">"Immediate cephalosporin hypersensitivity: Allergy evaluation, skin testing, and cross-reactivity with other beta-lactam antibiotics"</a>.)</p><p class="headingAnchor" id="H1301503787"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>A drug allergy may be defined as a specific immunologic reaction to a drug [<a href="#rid12">12</a>]. The classification and pathogenesis of drug allergies are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2086.html" rel="external">"Drug hypersensitivity: Classification and clinical features"</a> and  <a class="medical medical_review" href="/z/d/html/2072.html" rel="external">"Drug allergy: Pathogenesis"</a>.)</p><p class="headingAnchor" id="H3799010700"><span class="h2">Immediate versus delayed reactions</span><span class="headingEndMark"> — </span>The World Allergy Organization (WAO) has recommended categorizing immunologic drug reactions based upon the timing of the appearance of symptoms [<a href="#rid12">12</a>]. This system defines two broad categories of reactions: immediate and delayed. This division is intended to distinguish immunoglobulin E (IgE)-mediated (type I reactions), which account for many immediate reactions, from other types, because IgE-mediated reactions carry the risk of life-threatening anaphylaxis if the patient is re-exposed.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immediate reactions</strong> classically begin within one hour of the last administered dose and may begin within minutes. However, some immediate reactions appear after one hour, particularly if the drug was administered orally or taken with food. For these reasons, some guidelines include reactions beginning up to six hours after the last administered dose in the immediate category [<a href="#rid13">13-16</a>]. Nevertheless, the period of one hour identifies most immediate reactions associated with cephalosporins and other beta-lactam antibiotics. When sensitization (ie, formation of IgE) to a drug first develops, the initial symptoms may appear towards the end of a course of treatment but usually within one hour of the last administered dose and then typically escalate rapidly with any successive doses. Another common pattern is for symptoms to appear rapidly after the first dose of a subsequent course.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Delayed (or nonimmediate)</strong> <strong>reactions</strong> occur more than one hour after the initial drug administration [<a href="#rid14">14-16</a>]. Most delayed reactions begin after six hours and typically after days of treatment. Delayed reactions are more common than immediate reactions. They may be caused by several different mechanisms, but generally they are not IgE-mediated.</p><p></p><p>The classification and pathogenesis of allergic drug reactions are presented in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2086.html" rel="external">"Drug hypersensitivity: Classification and clinical features"</a> and  <a class="medical medical_review" href="/z/d/html/2072.html" rel="external">"Drug allergy: Pathogenesis"</a>.)</p><p class="headingAnchor" id="H99150999"><span class="h1">CLINICAL HISTORY</span><span class="headingEndMark"> — </span>The primary aims of the clinical history are to assess what type of reaction the patient likely experienced in the past, and to detect severe drug reactions, such as anaphylaxis (immediate), or Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) (delayed). The history of a drug reaction should ascertain the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Each exact agent reportedly associated with a reaction, and how it was administered (parenterally or orally)  (<a class="graphic graphic_table graphicRef115428" href="/z/d/graphic/115428.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The indication for its use (to make sure the reported drug is consistent with the indication).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The signs and symptoms of the reaction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>How long ago the reaction occurred (patients with more recent reactions are at higher risk for recurrence). (See <a class="local">'Natural history'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The timing of onset of the reaction (both from the precipitating dose, as well as from the initiation of that course of therapy).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Any treatment given and response to that treatment (including the duration of the reaction).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other concurrent medications, especially if they were new or temporary.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Any prior or subsequent history of exposure to the same drug or structurally similar drugs, with or without reactions. The source of this clinical history may be the patient, the medical record, a relative, the primary care physician, or a combination of sources.</p><p></p><p class="headingAnchor" id="H3250603591"><span class="h1">IMMEDIATE REACTIONS</span><span class="headingEndMark"> — </span>Immediate reactions are characterized by various combinations of flushing, urticaria, angioedema, rhinitis, bronchospasm, hypotension, and anaphylactic shock, usually developing within an hour of the last administered dose  (<a class="graphic graphic_table graphicRef100732" href="/z/d/graphic/100732.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H2966845422"><span class="h2">Signs and symptoms</span></p><p class="headingAnchor" id="H2957906022"><span class="h3">Urticaria with or without angioedema</span><span class="headingEndMark"> — </span>Many immediate reactions involve urticaria or hives, which are intensely pruritic, erythematous, cutaneous plaques or papules  (<a class="graphic graphic_picture graphicRef89752 graphicRef90165 graphicRef75230" href="/z/d/graphic/89752.html" rel="external">picture 1A-C</a>). Individual urticarial lesions resolve over the course of hours without residual markings, and then reappear elsewhere. Angioedema of the face, hands, or other areas may also be present, which develops within an hour or two of administration and resolves gradually over one to five days, depending upon severity. Careful attention should be paid to the patient's skin, both at the time of evaluation and when recording the details of the reaction in the patient's medical record, since accurate and detailed information can greatly facilitate later diagnosis and management.</p><p>Urticaria and angioedema developing rapidly after administration is considered an immediate reaction. However, urticaria and angioedema that develop later in the course of treatment may represent a form of delayed drug reaction, and these two reactions can be difficult or impossible to distinguish without an allergy evaluation if the clinical history is vague. (See <a class="local">'Delayed-onset urticaria/angioedema'</a> below.)</p><p>Occasionally, the diagnosis of potential drug allergy and the timing of a potential reaction is confused by an individual's underlying tendency to chronic urticaria. Patients should be asked if they are prone to developing urticaria in other situations, and whether they have ever had prolonged or unexplained episodes of urticaria and/or angioedema.</p><p class="headingAnchor" id="H1650791353"><span class="h3">Anaphylaxis</span><span class="headingEndMark"> — </span>Anaphylaxis, the most severe and potentially fatal form of immunoglobulin E (IgE)-mediated reaction, may present with a spectrum of possible signs and symptoms affecting multiple organ systems  (<a class="graphic graphic_table graphicRef100732" href="/z/d/graphic/100732.html" rel="external">table 2</a>) [<a href="#rid17">17-27</a>]. A typical presentation of drug-induced anaphylaxis would be rapid onset of urticaria, accompanied by pruritus, flushing, throat tightness, chest tightness or cough, possibly progressing to hypotension or shock. (See  <a class="medical medical_review" href="/z/d/html/106778.html" rel="external">"Anaphylaxis: Acute diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/392.html" rel="external">"Anaphylaxis: Emergency treatment"</a>.)</p><p>Some anaphylactic reactions to cephalosporins, such as <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a>, <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>, <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">cefazolin</a>, and <a class="drug drug_general" data-topicid="9230" href="/z/d/drug information/9230.html" rel="external">cefuroxime</a>, have caused a special type of vasospastic myocardial ischemia or infarction called Kounis syndrome [<a href="#rid27">27-37</a>], in which vasospasm of epicardial coronary arteries can occur in response to increased inflammatory mediators released during a hypersensitivity reaction [<a href="#rid38">38</a>].</p><p>The incidence of cephalosporin-induced anaphylaxis ranges from 0.6 to 6.8 cases per 100,000 exposures [<a href="#rid9">9,10,39,40</a>]. A particularly high incidence (6.8 cases per 100,000 exposures) was found in a Korean study [<a href="#rid10">10</a>], in which the incidence of fatal anaphylaxis was 0.1 cases per 100,000 exposures. In an American study, 33 (9 percent) of 368 fatalities, in which a culprit drug class could be identified, were due to cephalosporins [<a href="#rid41">41</a>].</p><p>An increasing number of anaphylactic reactions to cephalosporins have been reported in the last decade [<a href="#rid10">10,41-67</a>]. In a study recorded by the French Allergy Vigilance Network, cephalosporins were responsible for 12 percent of severe drug-induced anaphylaxis [<a href="#rid42">42</a>], whereas, in a Chinese study, they accounted for the majority (34.5 percent) of 467 antibiotic-induced anaphylaxis [<a href="#rid48">48</a>]. In a study of reported drug-induced anaphylaxis in the electronic health records of a large United States health care system, the prevalence of cephalosporin anaphylaxis was 6.1 per 10,000 [<a href="#rid49">49</a>].</p><p>Any cephalosporin can cause anaphylaxis [<a href="#rid10">10,17-37,40,42-58,61-146</a>], although <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">cefazolin</a>, <a class="drug drug_general" data-topicid="9211" href="/z/d/drug information/9211.html" rel="external">cefaclor</a>, <a class="drug drug_general" data-topicid="9230" href="/z/d/drug information/9230.html" rel="external">cefuroxime</a>, and <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> have been reported more often [<a href="#rid19">19,20,22,24,26,28-37,40,42-56,58,61-64,66-81,83-98,110,111,113,114,119-125,128-136,138,139,141-144,146</a>]. Parenterally-administered drugs may be more commonly implicated. Cases of anaphylaxis due to an occupational exposure to cephalosporins (eg, cefotiam and cefuroxime) have also been reported [<a href="#rid101">101,106,109,125-127,147</a>].</p><p class="headingAnchor" id="H3389286287"><span class="h3">Management of acute reactions</span><span class="headingEndMark"> — </span>The suspect cephalosporin should be discontinued and symptomatic treatments administered:</p><p class="bulletIndent1"><span class="glyph">●</span>Anaphylaxis is treated with intramuscular <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a>, as described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/392.html" rel="external">"Anaphylaxis: Emergency treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antihistamines are given for urticaria. Angioedema also responds to antihistamines, and glucocorticoids can be added for severe symptoms. Specific agents and dosing are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/8101.html" rel="external">"New-onset urticaria", section on 'Treatment'</a>.)</p><p></p><p>Photos of the reaction should be obtained by the patient or clinician and added to the patient's medical record for future reference. The causative drug should be listed as an allergy, with a description of the reaction and timing relative to the last administered dose. </p><p>The patient should be told to avoid all cephalosporins and penicillins until evaluated by an allergist, particularly if the reaction was anaphylaxis. Among patients with an immediate allergy to cephalosporins, less than two percent will react to penicillins, but immediate reactions can be dangerous. In addition, there may be higher rates of cross-reactivity between cephalosporins and penicillins that share common side chain groups, and an understanding of these patterns is important for choosing alternative drugs that are more likely to be tolerated. Referral to an allergist should be arranged whenever possible, because it is likely that the patient can be cleared to take penicillins and other cephalosporins. (See <a class="local">'Referral to an allergy specialist'</a> below.)</p><p class="headingAnchor" id="H1304353006"><span class="h2">Geographical differences</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">Cefazolin</a> has been responsible mainly for perioperative anaphylactic reactions worldwide, especially in North America [<a href="#rid26">26,33-35,37,40,42,44,46-48,52,54-56,58,62,63,65,67,97,110,111,113,114,130-132,134-136,138,139,142-144</a>]. Anaphylactic reactions to other cephalosporins, such as <a class="drug drug_general" data-topicid="9211" href="/z/d/drug information/9211.html" rel="external">cefaclor</a>, <a class="drug drug_general" data-topicid="9230" href="/z/d/drug information/9230.html" rel="external">cefuroxime</a>, <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a>, <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a>, and <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>, have also been reported worldwide, but mainly in European countries, such as Italy, Spain, and France [<a href="#rid19">19,20,22-24,27-32,36,40,42-45,47-51,53,58,62-64,66-98,116-125,128,129,133,141,145,146</a>]. Several anaphylactic reactions to cefaclor have been reported in Korea [<a href="#rid53">53,61,133</a>]. In China and Iran, ceftriaxone has been responsible for many deaths [<a href="#rid50">50,51</a>]. Ceftriaxone was also associated with the highest number of fatalities in an analysis of an Italian database [<a href="#rid141">141</a>]. Anaphylactic reactions to cefotiam, <a class="drug drug_general" data-topicid="9222" href="/z/d/drug information/9222.html" rel="external">cefotetan</a>, and cefoperazone have been reported almost exclusively in Japan, Korea, and China [<a href="#rid10">10,21,25,48,101,109,112,126,127,137,140</a>].</p><p class="headingAnchor" id="H4173657037"><span class="h2">Pathophysiology</span><span class="headingEndMark"> — </span>Immediate reactions occur in patients who have formed IgE antibodies against specific allergenic epitopes of a cephalosporin molecule, or a metabolite of the molecule, or the combination of the drug/metabolite conjugated to serum proteins. These reactions are classified as type I reactions in the Gell and Coombs system of immunologic reactions  (<a class="graphic graphic_table graphicRef80466" href="/z/d/graphic/80466.html" rel="external">table 3</a>). If a patient with these antibodies receives the same drug again, the drug (or its metabolite, etc) reacts with IgE bound to the surface of mast cells and basophils and leads to the wide-spread activation, degranulation, and release of vasoactive mediators from these cells. These mediators cause the signs and symptoms of immediate reactions.</p><p class="headingAnchor" id="H1697812573"><span class="h3">Possible allergens</span><span class="headingEndMark"> — </span>Patients may develop IgE antibodies against antigenic determinants that are unique to cephalosporins or to determinants that are shared with other beta-lactam drugs, particularly the penicillins [<a href="#rid148">148-153</a>]. The core structure of both penicillins and cephalosporins contains a four-membered beta-lactam ring  (<a class="graphic graphic_figure graphicRef69298" href="/z/d/graphic/69298.html" rel="external">figure 1</a>). Patients may become sensitized to the entire cephalosporin molecule (most common), the side chain groups, or to the beta-lactam core or its metabolites (least common), as discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/13536.html" rel="external">"Immediate cephalosporin hypersensitivity: Allergy evaluation, skin testing, and cross-reactivity with other beta-lactam antibiotics", section on 'Potential allergenic components'</a>.)</p><p class="headingAnchor" id="H3046240561"><span class="h3">The significance of side chain groups</span><span class="headingEndMark"> — </span>Penicillins and cephalosporins can be grouped according to similarities in the structures of side chain groups [<a href="#rid153">153-157</a>]. There are data to support side chain cross-reactivity within the same class of beta-lactams (eg, cephalosporins), as well as across different beta-lactam classes (eg, <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">aztreonam</a> and <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a>). However, the clinical relevance of these groupings and epidemiologic differences related to antibiotic use across populations has not been adequately studied. Thus, both of the following statements are accurate:</p><p class="bulletIndent1"><span class="glyph">●</span>It is not necessarily true that patients who have had an allergic reaction to a given cephalosporin will also react adversely to other cephalosporins or penicillins with identical or similar side groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Conversely, clinicians must not falsely assume that a cephalosporin-allergic patient will not react to another cephalosporin solely because it has a different side chain group from the culprit cephalosporin. Instead, it is better to be cautious and consult an allergy specialist for assistance with patients with severe past reactions.</p><p></p><p>Issues of cross-reactivity among cephalosporins and between cephalosporins and penicillins, carbapenems, and monobactams are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/13536.html" rel="external">"Immediate cephalosporin hypersensitivity: Allergy evaluation, skin testing, and cross-reactivity with other beta-lactam antibiotics"</a>.)</p><p class="headingAnchor" id="H91207512"><span class="h2">Cross-reactivity</span><span class="headingEndMark"> — </span>Patients with a possible immediate allergy to a cephalosporin should be advised to avoid all cephalosporins and penicillins until evaluated by an allergy specialist, particularly if the reaction was serious. In reality, such individuals may be able to receive other cephalosporins [<a href="#rid34">34,44,46,56,62,66,67,97,144</a>] and/or other beta-lactams including penicillins safely [<a href="#rid34">34,46,47,62,63,66,67,92,97,144</a>], although this is best determined through an allergy evaluation. (See <a class="local">'Referral to an allergy specialist'</a> below.)</p><p class="headingAnchor" id="H3338411625"><span class="h3">Among cephalosporins</span><span class="headingEndMark"> — </span>A significant percentage (ie, up to 43 percent in large studies) of patients who react to one cephalosporin will react to other cephalosporins and particularly those cephalosporins that have a shared R1 group [<a href="#rid44">44,67,74,81,89,92</a>]. One possible but important exception to this general statement may be patients with immediate reactions to <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">cefazolin</a>, which has R1 and R2 groups that are distinct from all other currently marketed beta-lactams, except ceftezole, a first generation cephalosporin that shares an identical R1 side chain and a similar R2 side chain with cefazolin [<a href="#rid155">155</a>]. Ceftezole, which is marketed under different trade names, is available in Italy, South Korea, and some Southeastern Asian countries. Several studies suggest that skin test-positive patients with past immediate reactions to cefazolin often tolerate other cephalosporins (except ceftezole) and other beta-lactams [<a href="#rid34">34,35,44,46,56,62,67,97,136,142-144</a>]. However, allergy evaluation is still advised whenever possible.</p><p class="headingAnchor" id="H3704967726"><span class="h3">Between cephalosporins and penicillins</span><span class="headingEndMark"> — </span>Most patients with immediate reactions to cephalosporins are allergic only to cephalosporins and <strong>not </strong>to penicillins [<a href="#rid34">34,46,47,62,63,66,67,92,97,144</a>]. Overall &lt;2 percent of patients allergic to cephalosporins will demonstrate clinical cross-reactivity to penicillins that do not share the same side chains. However, higher rates of skin test cross-reactivity (up to 30 percent) have been demonstrated between penicillins and cephalosporins that do share similar side chains, such as the aminocephalosporins (<a class="drug drug_general" data-topicid="9231" href="/z/d/drug information/9231.html" rel="external">cephalexin</a>, <a class="drug drug_general" data-topicid="9212" href="/z/d/drug information/9212.html" rel="external">cefadroxil</a>, and <a class="drug drug_general" data-topicid="9211" href="/z/d/drug information/9211.html" rel="external">cefaclor</a>) and the aminopenicillins (<a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a>, <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a>, bacampicillin), which are most commonly used in outpatient practice [<a href="#rid47">47,158</a>]. Studies showing these higher rates evaluated mainly European populations, and the corresponding rates in other populations are less well defined. In a study of Australian and American adults with histories of hypersensitivity reactions to cephalosporins and/or penicillins , 11 (6.3 percent) of the 174 patients who were initially labeled as allergic to aminocephalosporins had positive skin tests to ampicillin; all 11 patients had been labeled as allergic to cephalexin [<a href="#rid67">67</a>]. As had been seen in previously published studies This apparent aminopenicillin and aminocephalosporin cross-reactivity predominated in the Australian cohort of this study, as had been seen in previously published studies [<a href="#rid159">159</a>]. Therefore, because cross-reactivity between penicillins and cephalosporins does occur, allergy evaluation is advised whenever possible.</p><p class="headingAnchor" id="H4203330745"><span class="h3">With other beta-lactam drugs</span><span class="headingEndMark"> — </span>Patterns of cross-reactivity among different beta-lactam antibiotics, including carbapenems and monobactams, are summarized in the figure and discussed in further detail separately  (<a class="graphic graphic_figure graphicRef120774" href="/z/d/graphic/120774.html" rel="external">figure 2</a>). (See  <a class="medical medical_review" href="/z/d/html/13536.html" rel="external">"Immediate cephalosporin hypersensitivity: Allergy evaluation, skin testing, and cross-reactivity with other beta-lactam antibiotics", section on 'Use of related antibiotics in cephalosporin-allergic patients'</a>.)</p><p class="headingAnchor" id="H2962282413"><span class="h2">Natural history</span><span class="headingEndMark"> — </span>IgE-mediated allergy to beta-lactams, including cephalosporins, can resolve over time in patients who successfully avoid further exposure [<a href="#rid160">160,161</a>]. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/13536.html" rel="external">"Immediate cephalosporin hypersensitivity: Allergy evaluation, skin testing, and cross-reactivity with other beta-lactam antibiotics", section on 'Natural history'</a>.)</p><p class="headingAnchor" id="H4078219262"><span class="h2">Evaluation and diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of an immediate cephalosporin reaction that occurred in the past is based upon the clinical history, skin testing, and graded challenge (when appropriate) [<a href="#rid15">15,16,162,163</a>]. Skin testing and graded challenges are usually performed by allergy specialists, or other clinicians specifically trained in these techniques. (See  <a class="medical medical_review" href="/z/d/html/13536.html" rel="external">"Immediate cephalosporin hypersensitivity: Allergy evaluation, skin testing, and cross-reactivity with other beta-lactam antibiotics"</a>.)</p><p>As with other drug allergies, skin testing is not a reliable way to <strong>screen</strong> for cephalosporin allergy in a patient who never received a cephalosporin or who received one without an adverse reaction [<a href="#rid164">164</a>].</p><p class="headingAnchor" id="H610946013"><span class="h2">Referral to an allergy specialist</span><span class="headingEndMark"> — </span>Patients with past reactions to cephalosporins that are suspected to have been immediate reactions and who require subsequent use of other cephalosporins or penicillins should be evaluated by an allergy specialist. Isolated urticaria, with or without angioedema, can represent either an immediate or a delayed drug reaction, and it is difficult to distinguish the two based on clinical history alone because patients may not be clear about the timing of symptom onset. Therefore, we suggest allergy evaluation for these patients also. The purpose of this evaluation, which usually involves skin testing and graded challenge, is to determine what other drugs may be safely administered to that patient. Most patients will be able to tolerate other cephalosporins and/or penicillins [<a href="#rid34">34,44,46,47,56,62,63,66,67,92,97,144</a>].</p><p class="headingAnchor" id="H1490372358"><span class="h3">If referral is not feasible</span><span class="headingEndMark"> — </span>If referral to an allergist in the outpatient setting is not feasible or possible in a timely fashion, patients with suspected past immediate reactions should avoid all cephalosporins and penicillins if there are alternative antibiotics that can be used. However, if a cephalosporin or penicillin is considered the best option for a serious infection and there is no equivalent alternative antibiotic, then a graded challenge with an <strong>alternative</strong> cephalosporin or a penicillin can be performed, followed by formal outpatient allergy evaluation in the future. The choice of an alternative cephalosporin is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/13536.html" rel="external">"Immediate cephalosporin hypersensitivity: Allergy evaluation, skin testing, and cross-reactivity with other beta-lactam antibiotics", section on 'Graded challenge (Test dosing)'</a>.)</p><p class="headingAnchor" id="H457302431"><span class="h1">NONIMMEDIATE REACTIONS</span><span class="headingEndMark"> — </span>A large percentage of cephalosporin reactions are nonimmediate (or delayed) and consist of signs and symptoms limited to the skin. Most of these reactions will not recur upon re-exposure. Nonimmediate reactions most often consist of maculopapular or morbilliform cutaneous eruptions or delayed-onset urticaria and/or angioedema. In a pediatric series of 105 patients with nonimmediate/delayed reactions to cephalosporins, 58 demonstrated urticaria, 29 had maculopapular rash, 13 had erythema, 8 had both urticaria and angioedema, and 8 had isolated angioedema [<a href="#rid68">68</a>].</p><p>The pathogenesis of nonimmediate reactions seems to be heterogeneous and is not completely understood:</p><p class="bulletIndent1"><span class="glyph">●</span>Clinical and immunological studies suggest that a type IV (cell-mediated) pathogenic mechanism may be involved in some nonimmediate reactions, such as maculopapular, pustular, and bullous exanthemas  (<a class="graphic graphic_table graphicRef80466" href="/z/d/graphic/80466.html" rel="external">table 3</a>) [<a href="#rid165">165-167</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some nonimmediate cutaneous reactions may not represent drug hypersensitivity at all, but may simply be manifestations of the underlying viral infection itself or an interaction between the drug and the virus [<a href="#rid168">168</a>]. Similar to the known interaction with aminopenicillins, concomitant infection with certain viruses, such as Epstein-Barr virus (EBV), may predispose patients receiving cephalosporins to develop delayed cutaneous reactions [<a href="#rid169">169-172</a>].</p><p></p><p class="headingAnchor" id="H3981699835"><span class="h2">Common reactions (usually mild)</span><span class="headingEndMark"> — </span>The two most common types of nonimmediate reactions to cephalosporins are cutaneous maculopapular eruptions and delayed-onset urticaria and/or angioedema.</p><p class="headingAnchor" id="H1116029457"><span class="h3">Cutaneous maculopapular eruption</span><span class="headingEndMark"> — </span>Maculopapular or morbilliform eruptions are common adverse reactions to cephalosporins in both children and adults  (<a class="graphic graphic_picture graphicRef70062" href="/z/d/graphic/70062.html" rel="external">picture 2</a> and <a class="graphic graphic_picture graphicRef54205" href="/z/d/graphic/54205.html" rel="external">picture 3</a>) [<a href="#rid68">68,173-175</a>]. These are mostly mild and self-limited and are typically delayed in onset by several hours to days after the initiation of therapy [<a href="#rid68">68,173-175</a>]. The lesions of maculopapular drug eruptions are relatively fixed and last for several days, in contrast to urticarial lesions (which are transient, appear in crops, and then resolve within hours). (See  <a class="medical medical_review" href="/z/d/html/15762.html" rel="external">"Exanthematous (maculopapular) drug eruption"</a>.)</p><p class="headingAnchor" id="H18832722"><span class="h4">Acute management</span><span class="headingEndMark"> — </span>Acute management involves discontinuing the causative drug and symptomatic treatment if needed (see  <a class="medical medical_review" href="/z/d/html/15762.html" rel="external">"Exanthematous (maculopapular) drug eruption", section on 'Management'</a>). Photos of the reaction should be obtained by the patient or clinician and added to the patient's medical record for future reference. The causative drug should be listed as an allergy with a description of the reaction and its timing of onset relative to the last dose. The patient should be told to avoid the causative drug in the future, but other cephalosporins will likely be tolerated, as discussed below. Patients with delayed maculopapular eruptions to a cephalosporin generally do not need to avoid penicillins or other beta-lactams. (See <a class="local">'Evaluation and diagnosis'</a> below.)</p><p class="headingAnchor" id="H1718010344"><span class="h3">Delayed-onset urticaria/angioedema</span><span class="headingEndMark"> — </span>Urticaria and/or angioedema that appear several hours or days after the last administered dose are another common presentation of delayed cephalosporin reactions, in both children and adults [<a href="#rid68">68,173-175</a>]. In the pediatric series of 105 patients mentioned above, 58 of 116 nonimmediate reactions to cephalosporins in otherwise healthy children were urticarial eruptions [<a href="#rid68">68</a>]. Features that help distinguish these reactions from immediate reactions include the delayed onset of symptoms and the absence of other signs or symptoms of anaphylaxis, such as bronchospasm or hypotension. However, in reality, it can be difficult or impossible to determine from history alone if urticaria and angioedema resulted from a delayed or an immediate cephalosporin reaction. Because immediate allergy can progress to anaphylaxis with re-exposure, these patients should be evaluated for immediate allergy before they are given cephalosporins again [<a href="#rid68">68,174</a>]. (See <a class="local">'Referral to an allergy specialist'</a> above.)</p><p class="headingAnchor" id="H174163174"><span class="h4">Acute management</span><span class="headingEndMark"> — </span>Management involves discontinuing the causative drug and symptomatic treatment if needed (see  <a class="medical medical_review" href="/z/d/html/8101.html" rel="external">"New-onset urticaria", section on 'Treatment'</a>). Photos of the reaction should be obtained by the patient or clinician and added to the patient's medical record for future reference. The causative drug should be listed as an allergy, with a description of the reaction and its timing relative to the last dose. The patient should be told to avoid all cephalosporins and penicillins until evaluated by an allergist, as described in the next section.</p><p class="headingAnchor" id="H2058806338"><span class="h2">Evaluation and diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of a mild nonimmediate cephalosporin reaction is based upon the clinical history and physical exam (if signs or symptoms are still present). Further evaluation depends upon the presence of hives or angioedema:</p><p class="bulletIndent1"><span class="glyph">●</span>If the nonimmediate reaction involved hives or angioedema, we advocate evaluating for immunoglobulin E (IgE)-mediated allergy to the cephalosporin that caused the reaction, an alternative cephalosporin that is likely to be useful in the future, and penicillin. (See  <a class="medical medical_review" href="/z/d/html/13536.html" rel="external">"Immediate cephalosporin hypersensitivity: Allergy evaluation, skin testing, and cross-reactivity with other beta-lactam antibiotics"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the patient's past reaction did not involve hives or angioedema and was mild (eg, maculopapular rash lasting less than one week and without systemic symptoms), then a graded challenge to the desired cephalosporin can be performed. We generally avoid the same drug that caused the index reaction, but that drug can be used if it is superior for the treatment of a specific infection.</p><p></p><p>The utility of other types of testing for the diagnosis of nonimmediate reactions is debated and practice differs between European and American allergists [<a href="#rid166">166</a>]. Centers in Europe and Australia evaluate nonimmediate reactions with delayed reading of intradermal tests and/or patch testing followed by challenge if testing is negative and the index reaction was mild [<a href="#rid67">67,68,166,173-177</a>]. However, when delayed readings of intradermal tests and patch testing have been performed, the results are negative in most patients [<a href="#rid67">67,173-175</a>]. This may be particularly true in children, in whom delayed rashes temporarily associated with cephalosporins and other beta-lactams may be the result of a viral exanthem or a drug-infection interaction that does not reproduce on re-exposure. According to a 2020 European position paper, direct challenges (ie, without previous skin testing) with suspected cephalosporins or penicillins can be performed in children with mild maculopapular exanthemas (ie, limited or widespread rash; &lt;1-week duration, without systemic involvement) [<a href="#rid15">15</a>]. The following studies are representative: </p><p class="bulletIndent1"><span class="glyph">●</span>In a study from the author's center of 105 children with delayed reactions to cephalosporins, all had negative reactions to delayed readings of intradermal testing [<a href="#rid68">68</a>]. One hundred and four children with negative tests were offered challenge with the cephalosporin that caused the index reaction, 95 accepted, and all tolerated the drug. One patient developed hives to a suspension of the drug, but tolerated it in capsules, indicating that the reaction was due to an excipient [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a similar study of 105 adults with nonimmediate reactions, only five patients demonstrated positive responses to delayed-reading intradermal tests with the responsible cephalosporins [<a href="#rid174">174</a>]. Of those with negative delayed readings, 86 agreed to be challenged, and all tolerated the drug. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the aforementioned study of Australian and American adults, 7 (8.4 percent) of the 83 adults with histories of nonimmediate reactions to cephalosporins had positive delayed-reading intradermal tests to a cephalosporin [<a href="#rid67">67</a>]. Another study evaluated 91 patients ranging from 12 to 93 years with such histories by performing patch tests; 4 subjects (4.4 percent) were positive [<a href="#rid175">175</a>].</p><p></p><p>The author's approach to diagnosis in patients with mild nonimmediate cutaneous reactions to a specific cephalosporin, and where a sterile injectable preparation of the drug is available, is to perform delayed-reading intradermal skin testing, and if this is negative, graded challenge is performed [<a href="#rid178">178</a>]. The argument in favor of performing delayed-reading skin testing is that it can further improve the safety of graded challenge. </p><p>In the United States, the more common approach is to base the diagnosis on clinical features, with skin testing to exclude immediate allergy if the index reaction involved urticaria and angioedema, and challenge to prove tolerance. However, an increasing number of allergy and dermatology specialist centers are performing delayed-readings of intradermal skin testing and patch testing [<a href="#rid67">67,166,179</a>].</p><p class="headingAnchor" id="H2582625412"><span class="h3">Challenge procedures</span><span class="headingEndMark"> — </span>For patients with past nonimmediate (delayed) index reactions that were mild (exanthem [rash], isolated urticaria and/or angioedema) who subsequently require a cephalosporin, challenge procedures are not standardized and different experts have distinct approaches. The optimal approach is not known, and the issues with such challenges are described in this section. The limitations of challenges should be explained to patients.</p><p>In general, challenge (also called test dosing) protocols are based upon the time course of the patient's reaction and the pharmacology of the drug involved. Many different protocols have been described, ranging from graded challenge, to full single-dose challenge, to multiple-day procedures, although multiple-day challenges are not commonly done outside of specialty drug allergy centers. Of note, the lack of a response to a challenge may not preclude a recurrent nonimmediate reaction with full therapeutic treatment. Specifically, studies of penicillin reactions have documented that some delayed reactions only develop after several days of a full therapeutic dose or only in the presence of a concomitant viral infection [<a href="#rid180">180-182</a>].   </p><p>Regional differences in practice exist, although a common and pragmatic approach to challenge in patients whose index reactions were mild and delayed is to administer 1/10<sup>th</sup> of a full therapeutic dose, and if there is no reaction within one hour, to give a full dose, followed by another hour of observation. Another common approach is to administer the full dose as a single-step challenge and observe for one hour. Delayed reactions can occur up to 48 hours later (and up to eight days later, in rare cases), and the patient should be informed about this, although these reactions are generally mild [<a href="#rid183">183</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In one study of patients who had negative allergy evaluations followed by a one-day, full-dose challenge, subjects were investigated with a questionnaire to determine if they had subsequently taken the beta-lactam antibiotic in question again [<a href="#rid183">183</a>]. Among the 371 subjects with nonimmediate index reactions, the one-day challenge had a negative predictive value (NPV) of 94.9 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The author's approach to challenging adults with past mild delayed reactions and negative delayed-reading intradermal tests is to give 1/10<sup>th</sup> of the maximum single unit dose and, if tolerated, to administer a full dose one to seven days after, depending on the time interval of the index reaction [<a href="#rid15">15,174</a>]. However, this approach may not be practical in many settings. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>According to a European position paper, if the patient requires therapy at the time of the challenge, the one-tenth dose (if tolerated) should be followed one hour later by a full dose [<a href="#rid15">15</a>]. If a full dose is tolerated, a normal course of the drug can be administered.</p><p></p><p class="headingAnchor" id="H850997724"><span class="h2">Uncommon reactions (more severe)</span><span class="headingEndMark"> — </span>Cephalosporins have been associated with other types of nonimmediate hypersensitivity reactions that can be severe and even life-threatening, including the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Severe blistering cutaneous reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) [<a href="#rid51">51,184-187</a>], acute generalized exanthematous pustulosis (AGEP) [<a href="#rid176">176,187-192</a>], and erythroderma [<a href="#rid193">193,194</a>]. Patients with these severe reactions should never be exposed to the causative drug again. (See  <a class="medical medical_review" href="/z/d/html/2091.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/15761.html" rel="external">"Acute generalized exanthematous pustulosis (AGEP)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute localized exanthematous pustulosis [<a href="#rid195">195,196</a>]. (See  <a class="medical medical_review" href="/z/d/html/15761.html" rel="external">"Acute generalized exanthematous pustulosis (AGEP)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Isolated fever [<a href="#rid197">197,198</a>] and isolated eosinophilia [<a href="#rid199">199,200</a>]. (See  <a class="medical medical_review" href="/z/d/html/2738.html" rel="external">"Drug fever"</a> and  <a class="medical medical_review" href="/z/d/html/5691.html" rel="external">"Approach to the patient with unexplained eosinophilia", section on 'Causes of eosinophilia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drug reaction with eosinophilia and systemic symptoms (DRESS), also called drug-induced hypersensitivity syndrome (DiHS) [<a href="#rid51">51,175,176,187,192,201-209</a>]: DRESS/DiHS can be associated with involvement of internal organs such as hepatitis or interstitial nephritis and rarely can occur in association with cephalosporins in the absence of skin involvement or other features of DRESS. (See  <a class="medical medical_review" href="/z/d/html/2086.html" rel="external">"Drug hypersensitivity: Classification and clinical features", section on 'Type IV reactions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum sickness-like reactions (SSLRs), present with fever, arthralgias, and rash (eg, painful urticarial plaques) [<a href="#rid210">210</a>]: <a class="drug drug_general" data-topicid="9211" href="/z/d/drug information/9211.html" rel="external">Cefaclor</a>, in particular can cause SSLRs in children, possibly due to a genetic defect in metabolism of this specific drug [<a href="#rid211">211</a>]. Serum sickness-like reactions to cephalosporins (especially cefaclor and <a class="drug drug_general" data-topicid="9225" href="/z/d/drug information/9225.html" rel="external">cefprozil</a>) are thought to be due to altered drug metabolism, rather than antibody formation [<a href="#rid212">212</a>]. Patients with cefaclor-associated SSLR can receive other cephalosporins normally in the future, including the structurally similar agent loracarbef [<a href="#rid213">213</a>]. (See  <a class="medical medical_review" href="/z/d/html/2078.html" rel="external">"Serum sickness and serum sickness-like reactions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Linear immunoglobulin A (IgA) bullous dermatosis [<a href="#rid214">214</a>]: Linear IgA bullous dermatosis is classically associated with <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>, although it may occur with beta-lactams and other antibiotics. It may present with lesions on the skin, on the mucous membranes, or in both locations. (See  <a class="medical medical_review" href="/z/d/html/15301.html" rel="external">"Linear IgA bullous dermatosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fixed drug eruptions (FDE) [<a href="#rid215">215,216</a>]: Cephalosporins are an uncommon cause of fixed drug eruption, which typically present with solitary round to oval, dusky red to brown/black macules that may evolve into edematous plaques or bullae  (<a class="graphic graphic_picture graphicRef52192 graphicRef86671 graphicRef67733" href="/z/d/graphic/52192.html" rel="external">picture 4A-C</a>). Sites of predilection include the lips, genitalia, perianal area, and extremities. Acute lesions usually develop 30 minutes to 8 hours after drug administration and resolve spontaneously in 7 to 10 days. Severe forms like generalized bullous FDE, which can share features of SJS, have also been reported [<a href="#rid217">217</a>]. (See  <a class="medical medical_review" href="/z/d/html/15760.html" rel="external">"Fixed drug eruption"</a>.)</p><p></p><p class="headingAnchor" id="H463556122"><span class="h3">Use of related drugs following a severe delayed reaction</span><span class="headingEndMark"> — </span>Individuals with a history of SJS/TEN or DRESS/DiHS while taking a cephalosporin should avoid all cephalosporins, and especially avoid those cephalosporins that share R1 or R2 side chain with the culprit cephalosporin, unless there is a critical clinical indication such that the potential benefit outweighs any risk. This cautious approach is appropriate because re-exposure in a patient with SJS/TEN or DRESS carries the risk of reactivation of the reaction, which can cause significant short- and long-term morbidity or death. The same approach applies to AGEP, although cross-reactivity patterns have not been well-established, and AGEP is not associated with any known mortality or long-term morbidity. However, a cautious approach is appropriate in most situations involving these severe reactions, until more data are available.  </p><p>In patients with SJS/TEN, DRESS/DiHS, and AGEP to a cephalosporin, it is usually prudent to avoid penicillins also, particularly those containing the same side chains (eg, aminopenicillins) and other beta-lactams sharing side chains with the culprit drug (eg, <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">aztreonam</a> if the culprit was <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a>). In contrast, carbapenems are generally considered safe in the setting of severe cutaneous adverse drug reactions or organ-specific hypersensitivity to cephalosporins, due to very low cross-reactivity, and aztreonam could be used if ceftazidime was not the culprit. A few studies have evaluated the safety of using aztreonam [<a href="#rid192">192,218</a>] or carbapenems [<a href="#rid219">219</a>] in patients with past severe reactions to penicillins. In a study from the author's center [<a href="#rid218">218</a>], seven patients with severe T cell-mediated hypersensitivity to aminopenicillins (five with TEN and two with AGEP) were negative to aztreonam skin tests and tolerated aztreonam challenges. In another study from the same center [<a href="#rid219">219</a>], four patients with TEN and three with AGEP tolerated carbapenems (ie, <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">imipenem</a>/cilastatin, <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a>, and <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">ertapenem</a>) found negative in skin testing.</p><p>Research is ongoing into the evaluation of these severe delayed reactions and the safety of using related beta-lactams in the future. In European centers, patients with severe nonimmediate reactions, such as SJS/TEN, DRESS/DiHS, and AGEP are evaluated by both patch tests and delayed-reading intradermal tests [<a href="#rid15">15,176,177,192,218,220</a>]. In patients with more significant reactions, such as DRESS/DiHS, it is recommended that this type of testing be delayed at least six months after the acute reaction has subsided to avoid confusion with DRESS/DIHS relapse should a recurrence of symptoms occur. Patch tests are performed first (ie, prior to intradermal tests) and, if positive, intradermal tests are avoided. The sensitivity of patch testing for most types of drug-induced SJS/TEN is &lt;40 percent [<a href="#rid166">166,221</a>]. If patch tests are negative, intradermal tests are performed using higher drug dilutions [<a href="#rid15">15,220</a>]. However, the positive and negative predictive values of patch tests or intradermal tests have not been fully defined, because in many studies, challenges to confirm true reactivity are not performed given the severity of these reactions [<a href="#rid15">15,176,222</a>]. </p><p class="headingAnchor" id="H1167049152"><span class="h3">Milder reactions</span><span class="headingEndMark"> — </span>Milder reactions, such as serum sickness-like reactions (SSLRs), occur with both aminopenicillins and aminocephalosporins and are not a reason to avoid implicated or cross-reactive drugs indefinitely in the future. Studies on SSLR suggest that these reactions are less likely to recur with time and often do not recur on rechallenge in older children [<a href="#rid223">223</a>]. Similarly, single lesion, non-bullous, FDEs are milder reactions that may not preclude rechallenge with the implicated or potentially cross-reactive cephalosporins if there is clear benefit to treatment.  </p><p class="headingAnchor" id="H784158381"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109237.html" rel="external">"Society guideline links: Drug allergy and hypersensitivity"</a>.)</p><p class="headingAnchor" id="H2712910104"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Use of cephalosporins is increasing, and this class of antibiotics can cause a range of hypersensitivity reactions. Drug hypersensitivity reactions may be broadly divided into immediate reactions, which develop rapidly (ie, within minutes to six hours) following administration, and nonimmediate (or delayed) reactions, which begin hours to days into a course of treatment. (See <a class="local">'Definitions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immediate reactions to cephalosporins are primarily immunoglobulin E (IgE)-mediated reactions, such as urticaria, angioedema, or anaphylaxis  (<a class="graphic graphic_table graphicRef100732" href="/z/d/graphic/100732.html" rel="external">table 2</a>). Patients with a possible immediate allergy to a cephalosporin should be advised to avoid all cephalosporins and penicillins until evaluated by an allergy specialist, particularly if the reaction was serious. In reality, such individuals may be able to receive other cephalosporins and/or other beta-lactams (including penicillins) safely, although this is best determined through an allergy evaluation. (See <a class="local">'Immediate reactions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of IgE-mediated immediate allergy to cephalosporins involves clinical history, skin testing to cephalosporins and penicillin determinants, and a challenge procedure when possible. Referral to an allergist is indicated if the patient is likely to require therapy with cephalosporins or penicillins in the future. (See <a class="local">'Evaluation and diagnosis'</a> above and  <a class="medical medical_review" href="/z/d/html/13536.html" rel="external">"Immediate cephalosporin hypersensitivity: Allergy evaluation, skin testing, and cross-reactivity with other beta-lactam antibiotics", section on 'Skin testing'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Isolated urticaria and/or angioedema can represent either an immediate or a nonimmediate reaction. Therefore, all patients with urticaria and/or angioedema, regardless of the timing of onset, should undergo an evaluation for IgE-mediated allergy. (See <a class="local">'Evaluation and diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If referral to an allergist is not possible, and a cephalosporin or penicillin is considered the best option for a serious infection and there is no equivalent alternative antibiotic, then a graded challenge with an <strong>alternative</strong> cephalosporin or penicillin with different side chain structures can be performed, followed by formal outpatient allergy evaluation in the future. (See  <a class="medical medical_review" href="/z/d/html/13536.html" rel="external">"Immediate cephalosporin hypersensitivity: Allergy evaluation, skin testing, and cross-reactivity with other beta-lactam antibiotics", section on 'Graded challenge (Test dosing)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nonimmediate (delayed) reactions include common, mild reactions limited to the skin, such as maculopapular rash and delayed-onset urticaria and/or angioedema. The mechanisms involved in these reactions are not completely understood, but most of them will not recur upon re-exposure. The specific drug that caused the reaction is usually avoided in the future, although other cephalosporins with different side chain structures can be used. However, even the causative drug can be readministered using a challenge procedure if it is superior for the treatment of a specific infection. (See <a class="local">'Common reactions (usually mild)'</a> above and <a class="local">'Evaluation and diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Delayed urticaria and/or angioedema can be difficult or impossible to differentiate from immediate reactions if the timing of onset is unclear or the reaction occurred during the patient's first exposure to a drug. For this reason, we suggest that patients with delayed urticaria and/or angioedema undergo evaluation to exclude IgE-mediated immediate hypersensitivity, including skin testing and ingestion challenge. (See  <a class="medical medical_review" href="/z/d/html/13536.html" rel="external">"Immediate cephalosporin hypersensitivity: Allergy evaluation, skin testing, and cross-reactivity with other beta-lactam antibiotics", section on 'Graded challenge (Test dosing)'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with delayed maculopapular rash, skin testing for immediate hypersensitivity is not necessary, although European centers often evaluate these reactions with delayed readings of intradermal testing, patch testing, or both. These forms of testing are not standard practice in the United States, where delayed exanthema are diagnosed clinically. (See <a class="local">'Evaluation and diagnosis'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cephalosporins can also cause serum sickness-like reaction and more severe delayed reactions, such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP), and rarely single organ involvement such as drug-induced liver disease. Patients with these types of severe reactions to cephalosporins benefit from assessment by a specialist, such as an allergist and immunologist or dermatologist for information on the safety of future antibiotic use. In some cases, avoidance of all cephalosporins and often related penicillins and beta-lactams is warranted, although there are exceptions. (See <a class="local">'Uncommon reactions (more severe)'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA 1995; 273:214.</a></li><li><a class="nounderline abstract_t">Cars O, Mölstad S, Melander A. Variation in antibiotic use in the European Union. Lancet 2001; 357:1851.</a></li><li><a class="nounderline abstract_t">Ferech M, Coenen S, Malhotra-Kumar S, et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe. J Antimicrob Chemother 2006; 58:401.</a></li><li><a class="nounderline abstract_t">Versporten A, Coenen S, Adriaenssens N, et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient cephalosporin use in Europe (1997-2009). J Antimicrob Chemother 2011; 66 Suppl 6:vi25.</a></li><li><a class="nounderline abstract_t">Kelkar PS, Li JT. Cephalosporin allergy. N Engl J Med 2001; 345:804.</a></li><li><a class="nounderline abstract_t">Romano A, Torres MJ, Namour F, et al. Immediate hypersensitivity to cephalosporins. Allergy 2002; 57 Suppl 72:52.</a></li><li><a class="nounderline abstract_t">Madaan A, Li JT. Cephalosporin allergy. Immunol Allergy Clin North Am 2004; 24:463.</a></li><li><a class="nounderline abstract_t">Guéant JL, Guéant-Rodriguez RM, Viola M, et al. IgE-mediated hypersensitivity to cephalosporins. Curr Pharm Des 2006; 12:3335.</a></li><li><a class="nounderline abstract_t">Macy E, Contreras R. Adverse reactions associated with oral and parenteral use of cephalosporins: A retrospective population-based analysis. J Allergy Clin Immunol 2015; 135:745.</a></li><li><a class="nounderline abstract_t">Yang MS, Kang DY, Seo B, et al. Incidence of cephalosporin-induced anaphylaxis and clinical efficacy of screening intradermal tests with cephalosporins: A large multicenter retrospective cohort study. Allergy 2018; 73:1833.</a></li><li><a class="nounderline abstract_t">Norrby SR. Side effects of cephalosporins. Drugs 1987; 34 Suppl 2:105.</a></li><li><a class="nounderline abstract_t">Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113:832.</a></li><li><a class="nounderline abstract_t">Mirakian R, Leech SC, Krishna MT, et al. Management of allergy to penicillins and other beta-lactams. Clin Exp Allergy 2015; 45:300.</a></li><li><a class="nounderline abstract_t">Demoly P, Adkinson NF, Brockow K, et al. International Consensus on drug allergy. Allergy 2014; 69:420.</a></li><li><a class="nounderline abstract_t">Romano A, Atanaskovic-Markovic M, Barbaud A, et al. Towards a more precise diagnosis of hypersensitivity to beta-lactams - an EAACI position paper. Allergy 2020; 75:1300.</a></li><li><a class="nounderline abstract_t">Broyles AD, Banerji A, Castells M. Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: General Concepts. J Allergy Clin Immunol Pract 2020; 8:S3.</a></li><li><a class="nounderline abstract_t">Spruill FG, Minette LJ, Sturner WQ. Two surgical deaths associated with cephalothin. JAMA 1974; 229:440.</a></li><li><a class="nounderline abstract_t">Hoffman DR, Hudson P, Carlyle SJ, Massello W 3rd. Three cases of fatal anaphylaxis to antibiotics in patients with prior histories of allergy to the drug. Ann Allergy 1989; 62:91.</a></li><li><a class="nounderline abstract_t">Pumphrey RS, Davis S. Under-reporting of antibiotic anaphylaxis may put patients at risk. Lancet 1999; 353:1157.</a></li><li><a class="nounderline abstract_t">Trani N, Bonetti LR, Gualandri G, Barbolini G. Immediate anaphylactic death following antibiotics injection: splenic eosinophilia easily revealed by pagoda red stain. Forensic Sci Int 2008; 181:21.</a></li><li><a class="nounderline abstract_t">Tsujikawa K, Kuwayama K, Miyaguchi H, et al. A fatal case of suspected anaphylaxis with cefoperazone and sulbactam: LC-MS analysis. J Forensic Sci 2008; 53:226.</a></li><li><a class="nounderline abstract_t">Riezzo I, Bello S, Neri M, et al. Ceftriaxone intradermal test-related fatal anaphylactic shock: a medico-legal nightmare. Allergy 2010; 65:130.</a></li><li><a class="nounderline abstract_t">Spagnolo EV, Crisafulli G, Saitta S, et al. Fatal anaphylaxis in a 15-year-old boy with Down syndrome. J Paediatr Child Health 2011; 47:572.</a></li><li><a class="nounderline abstract_t">Calapai G, Imbesi S, Ventura-Spagnolo E, et al. Fatal Anaphylactic Shock Ceftriaxone-Induced in a 4-Year-Old Child. Pediatr Emerg Care 2016; 32:32.</a></li><li><a class="nounderline abstract_t">Osawa M, Satoh F, Horiuchi H, et al. Postmortem diagnosis of fatal anaphylaxis during intravenous administration of therapeutic and diagnostic agents: evaluation of clinical laboratory parameters and immunohistochemistry in three cases. Leg Med (Tokyo) 2008; 10:143.</a></li><li><a class="nounderline abstract_t">Carson HJ, Cook BA. Mast cell tryptase in a case of anaphylaxis due to repeat antibiotic exposure. Leg Med (Tokyo) 2009; 11:234.</a></li><li><a class="nounderline abstract_t">Kitulwatte I, Gangahawatte S, Perera U, Edirisinghe P. Death following ceftazidime-induced Kounis syndrome. Med Leg J 2017; 85:215.</a></li><li><a class="nounderline abstract_t">Ilhan E, Güvenç TS, Poyraz E, et al. Kounis Syndrome secondary to cefuroxime axetil use in an asthmatic patient. Int J Cardiol 2009; 137:e67.</a></li><li><a class="nounderline abstract_t">Caglar FN, Caglar IM, Coskun U, et al. Kounis syndrome: myocardial infarction secondary to an allergic insult--a rare clinical entity. Acta Cardiol 2011; 66:559.</a></li><li><a class="nounderline abstract_t">Ilgenli TF, Açıkalın A, Türkmen S, et al. ST elevation in inferior derivation, coronary ectasia, and slow coronary flow following ceftriaxone use. Am J Emerg Med 2012; 30:1657.e5.</a></li><li><a class="nounderline abstract_t">Yurtdaş M, Aydin MK. A case of coronary spasm with resultant acute myocardial infarction: likely the result of an allergic reaction. Intern Med 2012; 51:2161.</a></li><li><a class="nounderline abstract_t">Saleh AA. Kounis syndrome: acute inferior myocardial infarction with atroventricular node block due to ceftriaxone: a first reported case. Ann Saudi Med 2014; 34:250.</a></li><li><a class="nounderline abstract_t">Sánchez VO, Roca LC, Moreno Adel P. [Intraoperative "Kounis syndrome" that improved electrocardiography changes and hemodynamic situation after administering nitroglycerine]. Braz J Anesthesiol 2014; 64:281.</a></li><li><a class="nounderline abstract_t">Mota I, Gaspar Â, Morais-Almeida M. Perioperative Anaphylaxis Including Kounis Syndrome due to Selective Cefazolin Allergy. Int Arch Allergy Immunol 2018; 177:269.</a></li><li><a class="nounderline abstract_t">Sequeira T, Gaspar Â, Mota I, et al. Kounis Syndrome Associated With Selective Anaphylaxis to Cefazolin. J Investig Allergol Clin Immunol 2018; 28:257.</a></li><li><a class="nounderline abstract_t">Absmaier M, Biedermann T, Brockow K. Allergic myocardial infarction (Kounis syndrome) after cefuroxime with side-chain cross-reactivity. J Allergy Clin Immunol Pract 2018; 6:1781.</a></li><li><a class="nounderline abstract_t">Adachi H, Ihara M, Nojima Y, et al. Kounis syndrome caused by anaphylaxis without skin manifestations after cefazolin administration. J Allergy Clin Immunol Pract 2019; 7:317.</a></li><li><a class="nounderline abstract_t">Kounis NG, Zavras GM. Histamine-induced coronary artery spasm: the concept of allergic angina. Br J Clin Pract 1991; 45:121.</a></li><li><a class="nounderline abstract_t">International Collaborative Study of Severe Anaphylaxis. Risk of anaphylaxis in a hospital population in relation to the use of various drugs: an international study. Pharmacoepidemiol Drug Saf 2003; 12:195.</a></li><li><a class="nounderline abstract_t">Tejedor Alonso MA, Moro MM, Hernández JE, et al. Incidence of anaphylaxis in hospitalized patients. Int Arch Allergy Immunol 2011; 156:212.</a></li><li><a class="nounderline abstract_t">Jerschow E, Lin RY, Scaperotti MM, McGinn AP. Fatal anaphylaxis in the United States, 1999-2010: temporal patterns and demographic associations. J Allergy Clin Immunol 2014; 134:1318.</a></li><li><a class="nounderline abstract_t">Renaudin JM, Beaudouin E, Ponvert C, et al. Severe drug-induced anaphylaxis: analysis of 333 cases recorded by the Allergy Vigilance Network from 2002 to 2010. Allergy 2013; 68:929.</a></li><li><a class="nounderline abstract_t">Christiansen IS, Krøigaard M, Mosbech H, et al. Clinical and diagnostic features of perioperative hypersensitivity to cefuroxime. Clin Exp Allergy 2015; 45:807.</a></li><li><a class="nounderline abstract_t">Romano A, Gaeta F, Valluzzi RL, et al. IgE-mediated hypersensitivity to cephalosporins: Cross-reactivity and tolerability of alternative cephalosporins. J Allergy Clin Immunol 2015; 136:685.</a></li><li><a class="nounderline abstract_t">Sachs B, Fischer-Barth W, Merk HF. Reporting rates for severe hypersensitivity reactions associated with prescription-only drugs in outpatient treatment in Germany. Pharmacoepidemiol Drug Saf 2015; 24:1076.</a></li><li><a class="nounderline abstract_t">Uyttebroek AP, Decuyper II, Bridts CH, et al. Cefazolin Hypersensitivity: Toward Optimized Diagnosis. J Allergy Clin Immunol Pract 2016; 4:1232.</a></li><li><a class="nounderline abstract_t">Romano A, Gaeta F, Valluzzi RL, et al. IgE-mediated hypersensitivity to cephalosporins: cross-reactivity and tolerability of penicillins, monobactams, and carbapenems. J Allergy Clin Immunol 2010; 126:994.</a></li><li><a class="nounderline abstract_t">Zhao Y, Sun S, Li X, et al. Drug-induced anaphylaxis in China: a 10 year retrospective analysis of the Beijing Pharmacovigilance Database. Int J Clin Pharm 2018; 40:1349.</a></li><li><a class="nounderline abstract_t">Dhopeshwarkar N, Sheikh A, Doan R, et al. Drug-Induced Anaphylaxis Documented in Electronic Health Records. J Allergy Clin Immunol Pract 2019; 7:103.</a></li><li><a class="nounderline abstract_t">Yao Y, Zhou R, Wang Y. Fatal adverse effects of injected ceftriaxone sodium in China. Pharmacoepidemiol Drug Saf 2012; 21:1197.</a></li><li><a class="nounderline abstract_t">Shalviri G, Yousefian S, Gholami K. Adverse events induced by ceftriaxone: a 10-year review of reported cases to Iranian Pharmacovigilance Centre. J Clin Pharm Ther 2012; 37:448.</a></li><li><a class="nounderline abstract_t">Haslam S, Yen D, Dvirnik N, Engen D. Cefazolin use in patients who report a non-IgE mediated penicillin allergy: a retrospective look at adverse reactions in arthroplasty. Iowa Orthop J 2012; 32:100.</a></li><li><a class="nounderline abstract_t">Yoo HS, Kim SH, Kwon HS, et al. Immunologic evaluation of immediate hypersensitivity to cefaclor. Yonsei Med J 2014; 55:1473.</a></li><li><a class="nounderline abstract_t">Trautmann A, Seidl C, Stoevesandt J, Seitz CS. General anaesthesia-induced anaphylaxis: impact of allergy testing on subsequent anaesthesia. Clin Exp Allergy 2016; 46:125.</a></li><li><a class="nounderline abstract_t">Kuhlen JL Jr, Camargo CA Jr, Balekian DS, et al. Antibiotics Are the Most Commonly Identified Cause of Perioperative Hypersensitivity Reactions. J Allergy Clin Immunol Pract 2016; 4:697.</a></li><li><a class="nounderline abstract_t">Sadleir PH, Clarke RC, Platt PR. Cefalotin as antimicrobial prophylaxis in patients with known intraoperative anaphylaxis to cefazolin. Br J Anaesth 2016; 117:464.</a></li><li><a class="nounderline abstract_t">Mawhirt SL, Fonacier LS, Calixte R, et al. Skin testing and drug challenge outcomes in antibiotic-allergic patients with immediate-type hypersensitivity. Ann Allergy Asthma Immunol 2017; 118:73.</a></li><li><a class="nounderline abstract_t">Lee YS, Sun WZ. Epidemiology of anaphylaxis: A retrospective cohort study in Taiwan. Asian J Anesthesiol 2017; 55:9.</a></li><li><a class="nounderline abstract_t">Mulla ZD, Ebrahim MS, Gonzalez JL. Anaphylaxis in the obstetric patient: analysis of a statewide hospital discharge database. Ann Allergy Asthma Immunol 2010; 104:55.</a></li><li><a class="nounderline abstract_t">Tacquard C, Collange O, Gomis P, et al. Anaesthetic hypersensitivity reactions in France between 2011 and 2012: the 10th GERAP epidemiologic survey. Acta Anaesthesiol Scand 2017; 61:290.</a></li><li><a class="nounderline abstract_t">Nam YH, Lee SH, Rhyou HI, et al. Proper Cut-off Levels of Serum Specific IgE to Cefaclor for Patients with Cefaclor Allergy. Yonsei Med J 2018; 59:968.</a></li><li><a class="nounderline abstract_t">Yuson C, Kumar K, Le A, et al. Immediate cephalosporin allergy. Intern Med J 2019; 49:985.</a></li><li><a class="nounderline abstract_t">Li J, Green SL, Krupowicz BA, et al. Cross-reactivity to penicillins in cephalosporin anaphylaxis. Br J Anaesth 2019; 123:e532.</a></li><li><a class="nounderline abstract_t">Mori F, Liccioli G, Piccorossi A, et al. The Diagnosis of Ceftriaxone Hypersensitivity in a Paediatric Population. Int Arch Allergy Immunol 2019; 178:272.</a></li><li><a class="nounderline abstract_t">Van Gasse AL, Sabato V, Degerbeck F, et al. Specific IgE to cefazolin: Does it benefit diagnosis? J Allergy Clin Immunol Pract 2019; 7:2932.</a></li><li><a class="nounderline abstract_t">Van Gasse AL, Ebo DG, Faber MA, et al. Cross-reactivity in IgE-mediated allergy to cefuroxime: Focus on the R1 side chain. J Allergy Clin Immunol Pract 2020; 8:1094.</a></li><li><a class="nounderline abstract_t">Stone CA Jr, Trubiano JA, Phillips EJ. Testing Strategies and Predictors for Evaluating Immediate and Delayed Reactions to Cephalosporins. J Allergy Clin Immunol Pract 2021; 9:435.</a></li><li><a class="nounderline abstract_t">Romano A, Gaeta F, Valluzzi RL, et al. Diagnosing hypersensitivity reactions to cephalosporins in children. Pediatrics 2008; 122:521.</a></li><li><a class="nounderline abstract_t">Thiella G, Bucci L, Agrati AM, Palmieri G. Nonfatal anaphylactic shock following an unusual sensitization. J Occup Med 1989; 31:490.</a></li><li><a class="nounderline abstract_t">Yarbrough JA, Moffitt JE, Brown DA, Stafford CT. Cimetidine in the treatment of refractory anaphylaxis. Ann Allergy 1989; 63:235.</a></li><li><a class="nounderline abstract_t">VanArsdel PP Jr. Allergy to cephalosporins. JAMA 1991; 265:2254.</a></li><li><a class="nounderline abstract_t">Pepys J, Pepys EO, Baldo BA, Whitwam JG. Anaphylactic/anaphylactoid reactions to anaesthetic and associated agents. Skin prick tests in aetiological diagnosis. Anaesthesia 1994; 49:470.</a></li><li><a class="nounderline abstract_t">Marcos Bravo C, Luna Ortiz I, González Vázquez R. Hypersensitivity to cefuroxime with good tolerance to other betalactams. Allergy 1995; 50:359.</a></li><li><a class="nounderline abstract_t">Romano A, Quaratino D, Aimone-Gastin I, et al. Cephalosporin allergy: Characterization of unique and cross-reaction cephalosporin antigens. Int J Immunopathol Pharmacol 1997; 10:Suppl 2:187.</a></li><li><a class="nounderline abstract_t">Romano A, Quaratino D, Venuti A, et al. Selective type-1 hypersensitivity to cefuroxime. J Allergy Clin Immunol 1998; 101:564.</a></li><li><a class="nounderline abstract_t">Grouhi M, Hummel D, Roifman CM. Anaphylactic reaction to oral cefaclor in a child. Pediatrics 1999; 103:e50.</a></li><li><a class="nounderline abstract_t">Romano A, Quaratino D, Venemalm L, et al. A case of IgE-mediated hypersensitivity to ceftriaxone. J Allergy Clin Immunol 1999; 104:1113.</a></li><li><a class="nounderline abstract_t">Romano A, Piunti E, Di Fonso M, et al. Selective immediate hypersensitivity to ceftriaxone. Allergy 2000; 55:415.</a></li><li><a class="nounderline abstract_t">Demoly P, Messaad D, Sahla H, et al. Immediate hypersensitivity to ceftriaxone. Allergy 2000; 55:418.</a></li><li><a class="nounderline abstract_t">Bernardini R, Novembre E, Lombardi E, et al. Long persistence of IgE antibody to cefaclor. Allergy 2000; 55:984.</a></li><li><a class="nounderline abstract_t">Romano A, Mayorga C, Torres MJ, et al. Immediate allergic reactions to cephalosporins: cross-reactivity and selective responses. J Allergy Clin Immunol 2000; 106:1177.</a></li><li><a class="nounderline abstract_t">Romano A, Di Fonso M, Artesani MC, et al. Selective immediate hypersensitivity to ceftazidime. Allergy 2001; 56:84.</a></li><li><a class="nounderline abstract_t">Prosser DP, Gompels M. Anaphylactic shock due to cefuroxime in a patient taking penicillin prophylaxis. Paediatr Anaesth 2002; 12:73.</a></li><li><a class="nounderline abstract_t">Sáenz de San Pedro B, Mayorga C, Torres MJ, et al. Boosted IgE response after anaphylaxis reaction to cefuroxime with cross-reactivity with cefotaxime. Ann Allergy Asthma Immunol 2002; 89:101.</a></li><li><a class="nounderline abstract_t">Ernst MR, van Dijken PJ, Kabel PJ, Draaisma JM. Anaphylaxis after first exposure to ceftriaxone. Acta Paediatr 2002; 91:355.</a></li><li><a class="nounderline abstract_t">Baumgartner-Bonnevay C, Choquet-Kastylevsky G, Putet G, et al. [Anaphylactic shock associated with ceftriaxone therapy in a newborn]. Arch Pediatr 2002; 9:1050.</a></li><li><a class="nounderline abstract_t">Atanasković-Marković M, Gavrović-Jankulović M, Cirković Velicković T, et al. Type-I hypersensitivity to ceftriaxone and cross-reactivity with cefalexin and ampicillin. Allergy 2003; 58:537.</a></li><li><a class="nounderline abstract_t">Poston SA, Jennings HR, Poe KL. Cefazolin tolerance does not predict ceftriaxone hypersensitivity: unique side chains precipitate anaphylaxis. Pharmacotherapy 2004; 24:668.</a></li><li><a class="nounderline abstract_t">Romano A, Guéant-Rodriguez RM, Viola M, et al. Diagnosing immediate reactions to cephalosporins. Clin Exp Allergy 2005; 35:1234.</a></li><li><a class="nounderline abstract_t">Butler RH, Gupta R. Postcoital allergic reaction in a woman. J Emerg Med 2005; 28:153.</a></li><li><a class="nounderline abstract_t">Worthley DL, Gillis D, Kette F, Smith W. Radiocontrast anaphylaxis with failure of premedication. Intern Med J 2005; 35:58.</a></li><li><a class="nounderline abstract_t">Antunez C, Blanca-Lopez N, Torres MJ, et al. Immediate allergic reactions to cephalosporins: evaluation of cross-reactivity with a panel of penicillins and cephalosporins. J Allergy Clin Immunol 2006; 117:404.</a></li><li><a class="nounderline abstract_t">Hasdenteufel F, Luyasu S, Renaudin JM, et al. Anaphylactic shock associated with cefuroxime axetil: structure-activity relationships. Ann Pharmacother 2007; 41:1069.</a></li><li><a class="nounderline abstract_t">Khan R, Anastasakis E, Kadir RA. Anaphylactic reaction to ceftriaxone in labour. An emerging complication. J Obstet Gynaecol 2008; 28:751.</a></li><li><a class="nounderline abstract_t">Novembre E, Mori F, Pucci N, et al. Cefaclor anaphylaxis in children. Allergy 2009; 64:1233.</a></li><li><a class="nounderline abstract_t">Varela Losada S, González de la Cuesta C, Alvarez-Eire MG, González González C. Immediate-type allergic reaction to cefuroxime: cross-reactivity with other cephalosporins, and good tolerance to ceftazidime. J Investig Allergol Clin Immunol 2009; 19:164.</a></li><li><a class="nounderline abstract_t">Somech R, Weber EA, Lavi S. Evaluation of immediate allergic reactions to cephalosporins in non-penicillin-allergic patients. Int Arch Allergy Immunol 2009; 150:205.</a></li><li><a class="nounderline abstract_t">Caimmi S, Galéra C, Bousquet-Rouanet L, et al. Safety of cefuroxime as an alternative in patients with a proven hypersensitivity to penicillins: a DAHD cohort survey. Int Arch Allergy Immunol 2010; 153:53.</a></li><li><a class="nounderline abstract_t">Barnett AS, Hirshman CA. Anaphylactic reaction to cephapirin during spinal anesthesia. Anesth Analg 1979; 58:337.</a></li><li><a class="nounderline abstract_t">Bloomberg RJ. Cefotetan-induced anaphylaxis. Am J Obstet Gynecol 1988; 159:125.</a></li><li><a class="nounderline abstract_t">Mizutani H, Ohyanagi S, Shimizu M. Anaphylaxis from cefotiam hexetil hydrochloride (CTM-HE) in an atopic nurse. Clin Exp Dermatol 1996; 21:246.</a></li><li><a class="nounderline abstract_t">Nordt SP, Cantrell FL, Rodriguez GJ. Anaphylactic reaction to dermal exposure to cephalexin. Am J Emerg Med 1999; 17:492.</a></li><li><a class="nounderline abstract_t">Romano A, Torres MJ, Mayorga C, et al. Allergy to two drugs in a patient. Allergy 2001; 56:786.</a></li><li><a class="nounderline abstract_t">Orhan F, Odemis E, Yaris N, et al. A case of IgE-mediated hypersensitivity to cefepime. Allergy 2004; 59:239.</a></li><li><a class="nounderline abstract_t">Romano A, Viola M, Guéant-Rodriguez RM, et al. Selective immediate hypersensitivity to cefodizime. Allergy 2005; 60:1545.</a></li><li><a class="nounderline abstract_t">Kaplan K, Weinstein L. Anaphylaxis to cephaloridine in a nurse who prepared solutions of the drug. JAMA 1967; 200:75.</a></li><li><a class="nounderline abstract_t">Scholand JF, Tennenbaum JI, Cerilli GJ. Anaphylaxis to cephalothin in a patient allergic to penicillin. JAMA 1968; 206:130.</a></li><li><a class="nounderline abstract_t">Saleh Y, Tischler E. Severe anaphylactic reaction to intravenous cephaloridine in a pregnant patient. Med J Aust 1974; 2:490.</a></li><li><a class="nounderline abstract_t">Tadokoro K, Niimi N, Ohtoshi T, et al. Cefotiam-induced IgE-mediated occupational contact anaphylaxis of nurses; case reports, RAST analysis, and a review of the literature. Clin Exp Allergy 1994; 24:127.</a></li><li><a class="nounderline abstract_t">Konno R, Nagase S. Anaphylactic reaction to cefazolin in pregnancy. J Obstet Gynaecol (Tokyo 1995) 1995; 21:577.</a></li><li><a class="nounderline abstract_t">Warrington RJ, McPhillips S. Independent anaphylaxis to cefazolin without allergy to other beta-lactam antibiotics. J Allergy Clin Immunol 1996; 98:460.</a></li><li><a class="nounderline abstract_t">Fujita Y, Chikamitsu M, Kimura M, et al. An anaphylactic reaction possibly associated with an intraoperative coronary artery spasm during general anesthesia. J Clin Anesth 2001; 13:221.</a></li><li><a class="nounderline abstract_t">Jao MS, Cheng PJ, Shaw SW, Soong YK. Anaphylaxis to cefazolin during labor secondary to prophylaxis for group B Streptococcus: a case report. J Reprod Med 2006; 51:655.</a></li><li><a class="nounderline abstract_t">Tayman C, Mete E, Bayrak O, et al. Unexpected cefazolin anaphylaxis in a 5-month-old girl. Pediatr Emerg Care 2008; 24:344.</a></li><li><a class="nounderline abstract_t">Rothschild PD, Doty DB. Cephalothin reaction after penicillin sensitization. JAMA 1966; 196:372.</a></li><li><a class="nounderline abstract_t">Sengupta A, Kohli JK. Antibiotic prophylaxis in cesarean section causing anaphylaxis and intrauterine fetal death. J Obstet Gynaecol Res 2008; 34:252.</a></li><li><a class="nounderline abstract_t">Soyer OU, Ozen C, Tiras U, Dallar Y. Anaphylaxis in a neonate caused by ceftazidime. Allergy 2010; 65:1486.</a></li><li><a class="nounderline abstract_t">Moreno-Ancillo A, Gil-Adrados AC. Cefotaxim induced a near fatal anaphylactic shock in an infant. Allergol Immunopathol (Madr) 2012; 40:125.</a></li><li><a class="nounderline abstract_t">Sun RH, Hu BC, Li Q. Stress-induced cardiomyopathy complicated by multiple organ failure following cephalosporin-induced anaphylaxis. Intern Med 2012; 51:895.</a></li><li><a class="nounderline abstract_t">Del Villar-Guerra P, Moreno Vicente-Arche B, Castrillo Bustamante S, Santana Rodríguez C. Anaphylactic reaction due to cefuroxime axetil: A rare cause of anaphylaxis. Int J Immunopathol Pharmacol 2016; 29:731.</a></li><li><a class="nounderline abstract_t">Kim SY, Kim JH, Jang YS, et al. The Basophil Activation Test Is Safe and Useful for Confirming Drug-Induced Anaphylaxis. Allergy Asthma Immunol Res 2016; 8:541.</a></li><li><a class="nounderline abstract_t">Deguchi T, Shimomura Y, Hayashi R, et al. Cross-reactivity of cephalosporins: allergic immediate hypersensitivity to ceftriaxone in a cefcapene pivoxil-sensitized patient. Eur J Dermatol 2017; 27:187.</a></li><li><a class="nounderline abstract_t">Nag DS, Samaddar DP, Kant S, Mahanty PR. Perianesthetic refractory anaphylactic shock with cefuroxime in a patient with history of penicillin allergy on multiple antihypertensive medications. Braz J Anesthesiol 2017; 67:217.</a></li><li><a class="nounderline abstract_t">De Pasquale TM, Buonomo A, Di Gennaro L, Pucci S. Pulmonary Embolism After Ceftriaxone-Induced Anaphylaxis. J Investig Allergol Clin Immunol 2017; 27:190.</a></li><li><a class="nounderline abstract_t">Merget R, Sander I, Fartasch M, et al. Occupational generalized urticaria and anaphylaxis after inhalation of cefuroxime in a nurse. Am J Ind Med 2018; 61:261.</a></li><li><a class="nounderline abstract_t">Mizutani H, Ohyanagi S, Shimizu M. Anaphylactic shock related to occupational handling of Cefotiam dihydrochloride. Clin Exp Dermatol 1994; 19:449.</a></li><li><a class="nounderline abstract_t">Kim JE, Kim SH, Choi GS, et al. Detection of specific IgE antibodies to cefotiam-HSA conjugate by ELISA in a nurse with occupational anaphylaxis. Allergy 2010; 65:791.</a></li><li><a class="nounderline abstract_t">Nishioka K, Katayama I, Kobayashi Y, Takijiri C. Anaphylaxis due to cefaclor hypersensitivity. J Dermatol 1986; 13:226.</a></li><li><a class="nounderline abstract_t">Hama R, Mori K. High incidence of anaphylactic reactions to cefaclor. Lancet 1988; 1:1331.</a></li><li><a class="nounderline abstract_t">Berrocal AM, Schuman JS. Subconjunctival cephalosporin anaphylaxis. Ophthalmic Surg Lasers 2001; 32:79.</a></li><li><a class="nounderline abstract_t">Gibbs MW, Kuczkowski KM, Benumof JL. Complete recovery from prolonged cardio-pulmonary resuscitation following anaphylactic reaction to readministered intravenous cefazolin. Acta Anaesthesiol Scand 2003; 47:230.</a></li><li><a class="nounderline abstract_t">Lee CW, Castells MC. Perioperative anaphylaxis to cefazolin. Allergy Asthma Proc 2004; 25:23.</a></li><li><a class="nounderline abstract_t">Kim SH, Choi JH, Park HS. Heterogeneity of the IgE response to allergenic determinants of cefaclor in serum samples from patients with cefaclor-induced anaphylaxis. Ann Allergy Asthma Immunol 2005; 94:700.</a></li><li><a class="nounderline abstract_t">Borahay MA, Harirah HM, Olson G, et al. Disseminated Intravascular Coagulation, Hemoperitoneum, and Reversible Ischemic Neurological Deficit Complicating Anaphylaxis to Prophylactic Antibiotics during Cesarean Delivery: A Case Report and Review of Literature. AJP Rep 2011; 1:15.</a></li><li><a class="nounderline abstract_t">Lohsiriwat V, Sriyoscharti S, Raksakietisak M, Leelarasamee A. Three-day unrecognized cefazolin anaphylaxis in a case undergoing coronary bypass graft surgery. J Med Assoc Thai 2012; 95:825.</a></li><li><a class="nounderline abstract_t">Almeida JP, Lopes A, Campos Melo A, et al. Selective hypersensitivity to cefazolin and contribution of the basophil activation test. Eur Ann Allergy Clin Immunol 2017; 49:84.</a></li><li><a class="nounderline abstract_t">Jeon HJ, Ryu A, Min J, Kim NS. Maternal anaphylactic shock in pregnancy: A case report. Medicine (Baltimore) 2018; 97:e12351.</a></li><li><a class="nounderline abstract_t">Kuczkowski KM. Anaphylaxis and anesthesia. Minerva Anestesiol 2005; 71:54.</a></li><li><a class="nounderline abstract_t">Culp JA, Palis RI, Castells MC, et al. Perioperative anaphylaxis in a 44-year-old man. Allergy Asthma Proc 2007; 28:602.</a></li><li><a class="nounderline abstract_t">Suk EH, Kim DH, Kweon TD, et al. Stress-induced cardiomyopathy following cephalosporin-induced anaphylactic shock during general anesthesia. Can J Anaesth 2009; 56:432.</a></li><li><a class="nounderline abstract_t">Leone R, Sottosanti L, Luisa Iorio M, et al. Drug-related deaths: an analysis of the Italian spontaneous reporting database. Drug Saf 2008; 31:703.</a></li><li><a class="nounderline abstract_t">Igea JM, Fraj J, Davila I, et al. Allergy to cefazolin: study of in vivo cross reactivity with other betalactams. Ann Allergy 1992; 68:515.</a></li><li><a class="nounderline abstract_t">Weber EA. Cefazolin specific side chain hypersensitivity. J Allergy Clin Immunol 1996; 98:849.</a></li><li><a class="nounderline abstract_t">Pipet A, Veyrac G, Wessel F, et al. A statement on cefazolin immediate hypersensitivity: data from a large database, and focus on the cross-reactivities. Clin Exp Allergy 2011; 41:1602.</a></li><li><a class="nounderline abstract_t">Win PH, Brown H, Zankar A, et al. Rapid intravenous cephalosporin desensitization. J Allergy Clin Immunol 2005; 116:225.</a></li><li><a class="nounderline abstract_t">Fernandes RA, Regateiro FS, Pita J, et al. Severe Anaphylaxis With Cardiac Arrest Caused by Prick Test With Cefuroxime. J Investig Allergol Clin Immunol 2018; 28:426.</a></li><li><a class="nounderline abstract_t">Kim JE, Kim SH, Jin HJ, et al. IgE Sensitization to Cephalosporins in Health Care Workers. Allergy Asthma Immunol Res 2012; 4:85.</a></li><li><a class="nounderline abstract_t">Blanca M, Vega JM, Garcia J, et al. New aspects of allergic reactions to betalactams: crossreactions and unique specificities. Clin Exp Allergy 1994; 24:407.</a></li><li><a class="nounderline abstract_t">Pham NH, Baldo BA. beta-Lactam drug allergens: fine structural recognition patterns of cephalosporin-reactive IgE antibodies. J Mol Recognit 1996; 9:287.</a></li><li><a class="nounderline abstract_t">Baldo BA. Penicillins and cephalosporins as allergens--structural aspects of recognition and cross-reactions. Clin Exp Allergy 1999; 29:744.</a></li><li><a class="nounderline abstract_t">Blanca M, Mayorga C, Torres MJ, et al. Side-chain-specific reactions to betalactams: 14 years later. Clin Exp Allergy 2002; 32:192.</a></li><li><a class="nounderline abstract_t">Nagakura N, Shimizu T, Masuzawa T, Yanagihara Y. Anti-cephalexin monoclonal antibodies and their cross-reactivities to cephems and penams. Int Arch Allergy Appl Immunol 1990; 93:126.</a></li><li><a class="nounderline abstract_t">Romano A, Gaeta F, Arribas Poves MF, Valluzzi RL. Cross-Reactivity among Beta-Lactams. Curr Allergy Asthma Rep 2016; 16:24.</a></li><li><a class="nounderline abstract_t">Pichichero ME. A review of evidence supporting the American Academy of Pediatrics recommendation for prescribing cephalosporin antibiotics for penicillin-allergic patients. Pediatrics 2005; 115:1048.</a></li><li><a class="nounderline abstract_t">Zagursky RJ, Pichichero ME. Cross-reactivity in β-Lactam Allergy. J Allergy Clin Immunol Pract 2018; 6:72.</a></li><li><a class="nounderline abstract_t">Trubiano JA, Stone CA, Grayson ML, et al. The 3 Cs of Antibiotic Allergy-Classification, Cross-Reactivity, and Collaboration. J Allergy Clin Immunol Pract 2017; 5:1532.</a></li><li><a class="nounderline abstract_t">Picard M, Robitaille G, Karam F, et al. Cross-Reactivity to Cephalosporins and Carbapenems in Penicillin-Allergic Patients: Two Systematic Reviews and Meta-Analyses. J Allergy Clin Immunol Pract 2019; 7:2722.</a></li><li><a class="nounderline abstract_t">Romano A, Valluzzi RL, Caruso C, et al. Cross-Reactivity and Tolerability of Cephalosporins in Patients with IgE-Mediated Hypersensitivity to Penicillins. J Allergy Clin Immunol Pract 2018; 6:1662.</a></li><li><a class="nounderline abstract_t">Bourke J, Pavlos R, James I, Phillips E. Improving the Effectiveness of Penicillin Allergy De-labeling. J Allergy Clin Immunol Pract 2015; 3:365.</a></li><li><a class="nounderline abstract_t">Blanca M, Torres MJ, García JJ, et al. Natural evolution of skin test sensitivity in patients allergic to beta-lactam antibiotics. J Allergy Clin Immunol 1999; 103:918.</a></li><li><a class="nounderline abstract_t">Romano A, Gaeta F, Valluzzi RL, et al. Natural evolution of skin-test sensitivity in patients with IgE-mediated hypersensitivity to cephalosporins. Allergy 2014; 69:806.</a></li><li><a class="nounderline abstract_t">Blanca M, Romano A, Torres MJ, et al. Update on the evaluation of hypersensitivity reactions to betalactams. Allergy 2009; 64:183.</a></li><li><a class="nounderline abstract_t">Torres MJ, Blanca M, Fernandez J, et al. Diagnosis of immediate allergic reactions to beta-lactam antibiotics. Allergy 2003; 58:961.</a></li><li><a class="nounderline abstract_t">Yoon SY, Park SY, Kim S, et al. Validation of the cephalosporin intradermal skin test for predicting immediate hypersensitivity: a prospective study with drug challenge. Allergy 2013; 68:938.</a></li><li><a class="nounderline abstract_t">Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003; 139:683.</a></li><li><a class="nounderline abstract_t">Phillips EJ, Bigliardi P, Bircher AJ, et al. Controversies in drug allergy: Testing for delayed reactions. J Allergy Clin Immunol 2019; 143:66.</a></li><li><a class="nounderline abstract_t">Pichler WJ. Immune pathomechanism and classification of drug hypersensitivity. Allergy 2019; 74:1457.</a></li><li><a class="nounderline abstract_t">VanArsdel PP Jr. Drug reactions: allergy and near-allergy. Ann Allergy 1986; 57:305.</a></li><li><a class="nounderline abstract_t">Shiohara T, Kano Y. A complex interaction between drug allergy and viral infection. Clin Rev Allergy Immunol 2007; 33:124.</a></li><li><a class="nounderline abstract_t">McCloskey GL, Massa MC. Cephalexin rash in infectious mononucleosis. Cutis 1997; 59:251.</a></li><li><a class="nounderline abstract_t">Dibek Misirlioglu E, Guvenir H, Ozkaya Parlakay A, et al. Incidence of Antibiotic-Related Rash in Children with Epstein-Barr Virus Infection and Evaluation of the Frequency of Confirmed Antibiotic Hypersensitivity. Int Arch Allergy Immunol 2018; 176:33.</a></li><li><a class="nounderline abstract_t">Thompson DF, Ramos CL. Antibiotic-Induced Rash in Patients With Infectious Mononucleosis. Ann Pharmacother 2017; 51:154.</a></li><li><a class="nounderline abstract_t">Lammintausta K, Kortekangas-Savolainen O. The usefulness of skin tests to prove drug hypersensitivity. Br J Dermatol 2005; 152:968.</a></li><li><a class="nounderline abstract_t">Romano A, Gaeta F, Valluzzi RL, et al. Diagnosing nonimmediate reactions to cephalosporins. J Allergy Clin Immunol 2012; 129:1166.</a></li><li><a class="nounderline abstract_t">Pinho A, Coutinho I, Gameiro A, et al. Patch testing - a valuable tool for investigating non-immediate cutaneous adverse drug reactions to antibiotics. J Eur Acad Dermatol Venereol 2017; 31:280.</a></li><li><a class="nounderline abstract_t">Barbaud A, Collet E, Milpied B, et al. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol 2013; 168:555.</a></li><li><a class="nounderline abstract_t">Trubiano JA, Douglas AP, Goh M, et al. The safety of antibiotic skin testing in severe T-cell-mediated hypersensitivity of immunocompetent and immunocompromised hosts. J Allergy Clin Immunol Pract 2019; 7:1341.</a></li><li><a class="nounderline abstract_t">Romano A, Caubet JC. Antibiotic allergies in children and adults: from clinical symptoms to skin testing diagnosis. J Allergy Clin Immunol Pract 2014; 2:3.</a></li><li><a class="nounderline abstract_t">Derrick MI, Williams KB, Shade LMP, Phillips EJ. A survey of drug allergy training opportunities in the United States. J Allergy Clin Immunol Pract 2018; 6:302.</a></li><li><a class="nounderline abstract_t">Borch JE, Bindslev-Jensen C. Full-course drug challenge test in the diagnosis of delayed allergic reactions to penicillin. Int Arch Allergy Immunol 2011; 155:271.</a></li><li><a class="nounderline abstract_t">Blanca-López N, Zapatero L, Alonso E, et al. Skin testing and drug provocation in the diagnosis of nonimmediate reactions to aminopenicillins in children. Allergy 2009; 64:229.</a></li><li><a class="nounderline abstract_t">Schnyder B, Pichler WJ. Nonimmediate drug allergy: diagnostic benefit of skin testing and practical approach. J Allergy Clin Immunol 2012; 129:1170.</a></li><li><a class="nounderline abstract_t">Chiriac AM, Romano A, Ben Fadhel N, et al. Follow-up of patients with negative drug provocation tests to betalactams. Clin Exp Allergy 2019; 49:729.</a></li><li><a class="nounderline abstract_t">Murray KM, Camp MS. Cephalexin-induced Stevens-Johnson syndrome. Ann Pharmacother 1992; 26:1230.</a></li><li><a class="nounderline abstract_t">Narayanan VS, Mamatha GP, Ashok L, Rajashekar N. Steven Johnson syndrome due to I.V Ceftriaxone--a case report. Indian J Dent Res 2003; 14:220.</a></li><li><a class="nounderline abstract_t">Lam A, Randhawa I, Klaustermeyer W. Cephalosporin induced toxic epidermal necrolysis and subsequent penicillin drug exanthem. Allergol Int 2008; 57:281.</a></li><li><a class="nounderline abstract_t">Lin YF, Yang CH, Sindy H, et al. Severe cutaneous adverse reactions related to systemic antibiotics. Clin Infect Dis 2014; 58:1377.</a></li><li><a class="nounderline abstract_t">Belda Junior W, Ferolla AC. Acute generalized exanthematous pustulosis (AGEP). Case report. Rev Inst Med Trop Sao Paulo 2005; 47:171.</a></li><li><a class="nounderline abstract_t">Botelho LF, Picosse FR, Padilha MH, et al. Acute Generalized Exanthematous Pustulosis Induced by Cefepime: A Case Report. Case Rep Dermatol 2010; 2:82.</a></li><li><a class="nounderline abstract_t">Chaabane A, Aouam K, Gassab L, et al. Acute generalized exanthematous pustulosis (AGEP) induced by cefotaxime. Fundam Clin Pharmacol 2010; 24:429.</a></li><li><a class="nounderline abstract_t">Salman A, Yucelten D, Akin Cakici O, Kepenekli Kadayifci E. Acute generalized exanthematous pustulosis due to ceftriaxone: Report of a pediatric case with recurrence after positive patch test. Pediatr Dermatol 2019; 36:514.</a></li><li><a class="nounderline abstract_t">Bérot V, Gener G, Ingen-Housz-Oro S, et al. Cross-reactivity in beta-lactams after a non-immediate cutaneous adverse reaction: experience of a reference centre for toxic bullous diseases and severe cutaneous adverse reactions. J Eur Acad Dermatol Venereol 2020; 34:787.</a></li><li><a class="nounderline abstract_t">Gonzalo-Garijo MA, Rodríguez-Nevado I, de Argila D. Patch tests for diagnosis of delayed hypersensitivity to cephalosporins. Allergol Immunopathol (Madr) 2006; 34:39.</a></li><li><a class="nounderline abstract_t">Sousa AS, Lara OA, Papaiordanou F, et al. Acute generalized exanthematous pustulosis x Von Zumbusch's pustular psoriasis: a diagnostic challenge in a psoriatic patient. An Bras Dermatol 2015; 90:557.</a></li><li><a class="nounderline abstract_t">Qu YJ, Jin SB, Han XC, Zheng LQ. Acute localized exanthematous pustulosis caused by cefoperazone and sodium sulbactam. An Bras Dermatol 2016; 91:808.</a></li><li><a class="nounderline abstract_t">Dittmer M, Mutgi KAJ, Liu V, Swick BL. Localized, ovoid urticarial plaques with fine, nonfollicular pustules. Clin Exp Dermatol 2018; 43:209.</a></li><li><a class="nounderline abstract_t">Young EJ, Fainstein V, Musher DM. Drug-induced fever: cases seen in the evaluation of unexplained fever in a general hospital population. Rev Infect Dis 1982; 4:69.</a></li><li><a class="nounderline abstract_t">Mastella G, Agostini M, Barlocco G, et al. Alternative antibiotics for the treatment of Pseudomonas infections in cystic fibrosis. J Antimicrob Chemother 1983; 12 Suppl A:297.</a></li><li><a class="nounderline abstract_t">Platt R. Adverse effects of third-generation cephalosporins. J Antimicrob Chemother 1982; 10 Suppl C:135.</a></li><li><a class="nounderline abstract_t">Sanders CV, Greenberg RN, Marier RL. Cefamandole and cefoxitin. Ann Intern Med 1985; 103:70.</a></li><li><a class="nounderline abstract_t">Akcam FZ, Aygun FO, Akkaya VB. DRESS like severe drug rash with eosinophilia, atypic lymphocytosis and fever secondary to ceftriaxone. J Infect 2006; 53:e51.</a></li><li><a class="nounderline abstract_t">Suswardana, Hernanto M, Yudani BA, et al. DRESS syndrome from cefadroxil confirmed by positive patch test. Allergy 2007; 62:1216.</a></li><li><a class="nounderline abstract_t">Fujiwaki T, Yoshikawa T, Urashima R, Ishioka C. Drug rash with eosinophilia and systemic symptoms induced by cefotaxime and ampicillin. Pediatr Int 2008; 50:406.</a></li><li><a class="nounderline abstract_t">Garnier A, El Marabet el H, Kwon T, et al. Acute renal failure in a 3-year-old child as part of the drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome following hepatitis A. Pediatr Nephrol 2008; 23:667.</a></li><li><a class="nounderline abstract_t">An J, Lee JH, Lee H, et al. Drug rash with eosinophilia and systemic symptoms syndrome following cholestatic hepatitis A: a case report. Korean J Hepatol 2012; 18:84.</a></li><li><a class="nounderline abstract_t">Kang H, Min TK, Yang HJ, Pyun BY. Cefotaxime-induced drug rash with eosinophilia and systemic symptoms syndrome in a 7-year-old boy. Ann Allergy Asthma Immunol 2016; 117:202.</a></li><li><a class="nounderline abstract_t">Silva-Feistner M, Ortiz E, Rojas-Lechuga MJ, Muñoz D. [DRESS syndrome in paediatrics: Clinical case]. Rev Chil Pediatr 2017; 88:158.</a></li><li><a class="nounderline abstract_t">Karakayalı B, Yazar AS, Çakir D, et al. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome associated with cefotaxime and clindamycin use in a 6 year-old boy: a case report. Pan Afr Med J 2017; 28:218.</a></li><li><a class="nounderline abstract_t">Hansel K, Bellini V, Bianchi L, et al. Drug reaction with eosinophilia and systemic symptoms from ceftriaxone confirmed by positive patch test: An immunohistochemical study. J Allergy Clin Immunol Pract 2017; 5:808.</a></li><li><a class="nounderline abstract_t">Nguyen CV, Miller DD. Serum sickness-like drug reaction: two cases with a neutrophilic urticarial pattern. J Cutan Pathol 2017; 44:177.</a></li><li><a class="nounderline abstract_t">Yerushalmi J, Zvulunov A, Halevy S. Serum sickness-like reactions. Cutis 2002; 69:395.</a></li><li><a class="nounderline abstract_t">Kearns GL, Wheeler JG, Childress SH, Letzig LG. Serum sickness-like reactions to cefaclor: role of hepatic metabolism and individual susceptibility. J Pediatr 1994; 125:805.</a></li><li><a class="nounderline abstract_t">Kearns GL, Wheeler JG, Rieder MJ, Reid J. Serum sickness-like reaction to cefaclor: lack of in vitro cross-reactivity with loracarbef. Clin Pharmacol Ther 1998; 63:686.</a></li><li><a class="nounderline abstract_t">Yawalkar N, Reimers A, Hari Y, et al. Drug-induced linear IgA bullous dermatosis associated with ceftriaxone- and metronidazole-specific T cells. Dermatology 1999; 199:25.</a></li><li><a class="nounderline abstract_t">Ozkaya E, Mirzoyeva L, Jhaish MS. Ceftriaxone-induced fixed drug eruption: first report. Am J Clin Dermatol 2008; 9:345.</a></li><li><a class="nounderline abstract_t">Ben Mansour A, Bellon N, Frassati-Biaggi A, et al. Multifocal fixed drug eruption to ceftazidime in a child with cystic fibrosis. Pediatr Allergy Immunol 2018; 29:115.</a></li><li><a class="nounderline abstract_t">Mitre V, Applebaum DS, Albahrani Y, Hsu S. Generalized bullous fixed drug eruption imitating toxic epidermal necrolysis: a case report and literature review. Dermatol Online J 2017; 23.</a></li><li><a class="nounderline abstract_t">Romano A, Gaeta F, Valluzzi RL, et al. Cross-reactivity and tolerability of aztreonam and cephalosporins in subjects with a T cell-mediated hypersensitivity to penicillins. J Allergy Clin Immunol 2016; 138:179.</a></li><li><a class="nounderline abstract_t">Romano A, Gaeta F, Valluzzi RL, et al. Absence of cross-reactivity to carbapenems in patients with delayed hypersensitivity to penicillins. Allergy 2013; 68:1618.</a></li><li><a class="nounderline abstract_t">Brockow K, Romano A, Blanca M, et al. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 2002; 57:45.</a></li><li><a class="nounderline abstract_t">Barbaud A. Skin testing and patch testing in non-IgE-mediated drug allergy. Curr Allergy Asthma Rep 2014; 14:442.</a></li><li><a class="nounderline abstract_t">Torres MJ, Romano A, Celik G, et al. Approach to the diagnosis of drug hypersensitivity reactions: similarities and differences between Europe and North America. Clin Transl Allergy 2017; 7:7.</a></li><li><a class="nounderline abstract_t">Delli Colli L, Gabrielli S, Abrams EM, et al. Differentiating Between β-Lactam-Induced Serum Sickness-Like Reactions and Viral Exanthem in Children Using a Graded Oral Challenge. J Allergy Clin Immunol Pract 2021; 9:916.</a></li></ol></div><div id="topicVersionRevision">Topic 13535 Version 13.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7807660" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Trends in antimicrobial drug prescribing among office-based physicians in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11410197" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Variation in antibiotic use in the European Union.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16735414" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22096063" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : European Surveillance of Antimicrobial Consumption (ESAC): outpatient cephalosporin use in Europe (1997-2009).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11556301" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cephalosporin allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12144556" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Immediate hypersensitivity to cephalosporins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15242721" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cephalosporin allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17017928" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : IgE-mediated hypersensitivity to cephalosporins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25262461" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Adverse reactions associated with oral and parenteral use of cephalosporins: A retrospective population-based analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29517808" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Incidence of cephalosporin-induced anaphylaxis and clinical efficacy of screening intradermal tests with cephalosporins: A large multicenter retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3319495" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Side effects of cephalosporins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15131563" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25623506" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Management of allergy to penicillins and other beta-lactams.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24697291" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : International Consensus on drug allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31749148" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Towards a more precise diagnosis of hypersensitivity to beta-lactams - an EAACI position paper.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32791249" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: General Concepts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4406879" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Two surgical deaths associated with cephalothin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2919808" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Three cases of fatal anaphylaxis to antibiotics in patients with prior histories of allergy to the drug.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10209990" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Under-reporting of antibiotic anaphylaxis may put patients at risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18945565" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Immediate anaphylactic death following antibiotics injection: splenic eosinophilia easily revealed by pagoda red stain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18279263" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A fatal case of suspected anaphylaxis with cefoperazone and sulbactam: LC-MS analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20078505" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Ceftriaxone intradermal test-related fatal anaphylactic shock: a medico-legal nightmare.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21843193" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Fatal anaphylaxis in a 15-year-old boy with Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25513979" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Fatal Anaphylactic Shock Ceftriaxone-Induced in a 4-Year-Old Child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18035583" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Postmortem diagnosis of fatal anaphylaxis during intravenous administration of therapeutic and diagnostic agents: evaluation of clinical laboratory parameters and immunohistochemistry in three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19515597" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Mast cell tryptase in a case of anaphylaxis due to repeat antibiotic exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29210337" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Death following ceftazidime-induced Kounis syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19428133" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Kounis Syndrome secondary to cefuroxime axetil use in an asthmatic patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21894822" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Kounis syndrome: myocardial infarction secondary to an allergic insult--a rare clinical entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22100485" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : ST elevation in inferior derivation, coronary ectasia, and slow coronary flow following ceftriaxone use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22892496" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A case of coronary spasm with resultant acute myocardial infarction: likely the result of an allergic reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25266187" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Kounis syndrome: acute inferior myocardial infarction with atroventricular node block due to ceftriaxone: a first reported case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25096776" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : [Intraoperative "Kounis syndrome" that improved electrocardiography changes and hemodynamic situation after administering nitroglycerine].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29913447" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Perioperative Anaphylaxis Including Kounis Syndrome due to Selective Cefazolin Allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30073957" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Kounis Syndrome Associated With Selective Anaphylaxis to Cefazolin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29428243" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Allergic myocardial infarction (Kounis syndrome) after cefuroxime with side-chain cross-reactivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29902529" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Kounis syndrome caused by anaphylaxis without skin manifestations after cefazolin administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1793697" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Histamine-induced coronary artery spasm: the concept of allergic angina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12733472" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Risk of anaphylaxis in a hospital population in relation to the use of various drugs: an international study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21597302" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Incidence of anaphylaxis in hospitalized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25280385" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Fatal anaphylaxis in the United States, 1999-2010: temporal patterns and demographic associations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23741979" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Severe drug-induced anaphylaxis: analysis of 333 cases recorded by the Allergy Vigilance Network from 2002 to 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25395022" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Clinical and diagnostic features of perioperative hypersensitivity to cefuroxime.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25930196" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : IgE-mediated hypersensitivity to cephalosporins: Cross-reactivity and tolerability of alternative cephalosporins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26285651" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Reporting rates for severe hypersensitivity reactions associated with prescription-only drugs in outpatient treatment in Germany.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27317018" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Cefazolin Hypersensitivity: Toward Optimized Diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20888035" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : IgE-mediated hypersensitivity to cephalosporins: cross-reactivity and tolerability of penicillins, monobactams, and carbapenems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29086147" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Drug-induced anaphylaxis in China: a 10 year retrospective analysis of the Beijing Pharmacovigilance Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29969686" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Drug-Induced Anaphylaxis Documented in Electronic Health Records.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22761158" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Fatal adverse effects of injected ceftriaxone sodium in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22122488" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Adverse events induced by ceftriaxone: a 10-year review of reported cases to Iranian Pharmacovigilance Centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23576929" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Cefazolin use in patients who report a non-IgE mediated penicillin allergy: a retrospective look at adverse reactions in arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25323882" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Immunologic evaluation of immediate hypersensitivity to cefaclor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26767493" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : General anaesthesia-induced anaphylaxis: impact of allergy testing on subsequent anaesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27039234" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Antibiotics Are the Most Commonly Identified Cause of Perioperative Hypersensitivity Reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28077533" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cefalotin as antimicrobial prophylaxis in patients with known intraoperative anaphylaxis to cefazolin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27864093" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Skin testing and drug challenge outcomes in antibiotic-allergic patients with immediate-type hypersensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28258852" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Epidemiology of anaphylaxis: A retrospective cohort study in Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20143646" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Anaphylaxis in the obstetric patient: analysis of a statewide hospital discharge database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28164269" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Anaesthetic hypersensitivity reactions in France between 2011 and 2012: the 10th GERAP epidemiologic survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30187704" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Proper Cut-off Levels of Serum Specific IgE to Cefaclor for Patients with Cefaclor Allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30667130" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Immediate cephalosporin allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31604573" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Cross-reactivity to penicillins in cephalosporin anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30605910" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The Diagnosis of Ceftriaxone Hypersensitivity in a Paediatric Population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31229452" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Specific IgE to cefazolin: Does it benefit diagnosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31479769" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Cross-reactivity in IgE-mediated allergy to cefuroxime: Focus on the R1 side chain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32822918" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Testing Strategies and Predictors for Evaluating Immediate and Delayed Reactions to Cephalosporins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18762521" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Diagnosing hypersensitivity reactions to cephalosporins in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2715859" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Nonfatal anaphylactic shock following an unusual sensitization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2774306" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Cimetidine in the treatment of refractory anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2013960" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Allergy to cephalosporins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8017588" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Anaphylactic/anaphylactoid reactions to anaesthetic and associated agents. Skin prick tests in aetiological diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7573820" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Hypersensitivity to cefuroxime with good tolerance to other betalactams.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Cephalosporin allergy: Characterization of unique and cross-reaction cephalosporin antigens</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9564816" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Selective type-1 hypersensitivity to cefuroxime.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10103342" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Anaphylactic reaction to oral cefaclor in a child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10550764" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : A case of IgE-mediated hypersensitivity to ceftriaxone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10782539" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Selective immediate hypersensitivity to ceftriaxone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10782542" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Immediate hypersensitivity to ceftriaxone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11030389" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Long persistence of IgE antibody to cefaclor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11112903" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Immediate allergic reactions to cephalosporins: cross-reactivity and selective responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11167362" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Selective immediate hypersensitivity to ceftazidime.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11849580" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Anaphylactic shock due to cefuroxime in a patient taking penicillin prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12141712" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Boosted IgE response after anaphylaxis reaction to cefuroxime with cross-reactivity with cefotaxime.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12022312" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Anaphylaxis after first exposure to ceftriaxone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12462836" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : [Anaphylactic shock associated with ceftriaxone therapy in a newborn].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12757464" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Type-I hypersensitivity to ceftriaxone and cross-reactivity with cefalexin and ampicillin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15162902" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Cefazolin tolerance does not predict ceftriaxone hypersensitivity: unique side chains precipitate anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16164453" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Diagnosing immediate reactions to cephalosporins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15707809" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Postcoital allergic reaction in a woman.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15667471" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Radiocontrast anaphylaxis with failure of premedication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16461141" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Immediate allergic reactions to cephalosporins: evaluation of cross-reactivity with a panel of penicillins and cephalosporins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17488833" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Anaphylactic shock associated with cefuroxime axetil: structure-activity relationships.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19065378" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Anaphylactic reaction to ceftriaxone in labour. An emerging complication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19385950" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Cefaclor anaphylaxis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19476025" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Immediate-type allergic reaction to cefuroxime: cross-reactivity with other cephalosporins, and good tolerance to ceftazidime.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19494517" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Evaluation of immediate allergic reactions to cephalosporins in non-penicillin-allergic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20357485" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Safety of cefuroxime as an alternative in patients with a proven hypersensitivity to penicillins: a DAHD cohort survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/572184" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Anaphylactic reaction to cephapirin during spinal anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3164980" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Cefotetan-induced anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8914378" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Anaphylaxis from cefotiam hexetil hydrochloride (CTM-HE) in an atopic nurse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10496518" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Anaphylactic reaction to dermal exposure to cephalexin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11488676" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Allergy to two drugs in a patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14763949" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : A case of IgE-mediated hypersensitivity to cefepime.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16266391" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Selective immediate hypersensitivity to cefodizime.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6071861" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Anaphylaxis to cephaloridine in a nurse who prepared solutions of the drug.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5695436" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Anaphylaxis to cephalothin in a patient allergic to penicillin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4431354" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Severe anaphylactic reaction to intravenous cephaloridine in a pregnant patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7514490" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Cefotiam-induced IgE-mediated occupational contact anaphylaxis of nurses; case reports, RAST analysis, and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8640468" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Anaphylactic reaction to cefazolin in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8757224" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Independent anaphylaxis to cefazolin without allergy to other beta-lactam antibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11377162" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : An anaphylactic reaction possibly associated with an intraoperative coronary artery spasm during general anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16967637" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Anaphylaxis to cefazolin during labor secondary to prophylaxis for group B Streptococcus: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18496124" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Unexpected cefazolin anaphylaxis in a 5-month-old girl.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Cephalothin reaction after penicillin sensitization</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18412791" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Antibiotic prophylaxis in cesarean section causing anaphylaxis and intrauterine fetal death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20415719" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Anaphylaxis in a neonate caused by ceftazidime.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21621317" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Cefotaxim induced a near fatal anaphylactic shock in an infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22504246" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Stress-induced cardiomyopathy complicated by multiple organ failure following cephalosporin-induced anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27531605" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Anaphylactic reaction due to cefuroxime axetil: A rare cause of anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27582406" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : The Basophil Activation Test Is Safe and Useful for Confirming Drug-Induced Anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27934618" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Cross-reactivity of cephalosporins: allergic immediate hypersensitivity to ceftriaxone in a cefcapene pivoxil-sensitized patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28236873" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Perianesthetic refractory anaphylactic shock with cefuroxime in a patient with history of penicillin allergy on multiple antihypertensive medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28570226" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Pulmonary Embolism After Ceftriaxone-Induced Anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29114903" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Occupational generalized urticaria and anaphylaxis after inhalation of cefuroxime in a nurse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7955515" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Anaphylactic shock related to occupational handling of Cefotiam dihydrochloride.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19886926" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Detection of specific IgE antibodies to cefotiam-HSA conjugate by ELISA in a nurse with occupational anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3537051" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Anaphylaxis due to cefaclor hypersensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2897571" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : High incidence of anaphylactic reactions to cefaclor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11195750" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Subconjunctival cephalosporin anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12631055" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Complete recovery from prolonged cardio-pulmonary resuscitation following anaphylactic reaction to readministered intravenous cefazolin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15055557" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Perioperative anaphylaxis to cefazolin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15984605" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Heterogeneity of the IgE response to allergenic determinants of cefaclor in serum samples from patients with cefaclor-induced anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23705078" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Disseminated Intravascular Coagulation, Hemoperitoneum, and Reversible Ischemic Neurological Deficit Complicating Anaphylaxis to Prophylactic Antibiotics during Cesarean Delivery: A Case Report and Review of Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22774629" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Three-day unrecognized cefazolin anaphylaxis in a case undergoing coronary bypass graft surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28294589" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Selective hypersensitivity to cefazolin and contribution of the basophil activation test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30212990" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Maternal anaphylactic shock in pregnancy: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15711507" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Anaphylaxis and anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18034982" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Perioperative anaphylaxis in a 44-year-old man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19322620" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Stress-induced cardiomyopathy following cephalosporin-induced anaphylactic shock during general anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18636789" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Drug-related deaths: an analysis of the Italian spontaneous reporting database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1376972" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Allergy to cefazolin: study of in vivo cross reactivity with other betalactams.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8876565" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Cefazolin specific side chain hypersensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22093010" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : A statement on cefazolin immediate hypersensitivity: data from a large database, and focus on the cross-reactivities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15990801" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Rapid intravenous cephalosporin desensitization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30530392" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Severe Anaphylaxis With Cardiac Arrest Caused by Prick Test With Cefuroxime.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22379603" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : IgE Sensitization to Cephalosporins in Health Care Workers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8087651" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : New aspects of allergic reactions to betalactams: crossreactions and unique specificities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9131470" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : beta-Lactam drug allergens: fine structural recognition patterns of cephalosporin-reactive IgE antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10336588" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Penicillins and cephalosporins as allergens--structural aspects of recognition and cross-reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11929481" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Side-chain-specific reactions to betalactams: 14 years later.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2099340" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Anti-cephalexin monoclonal antibodies and their cross-reactivities to cephems and penams.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26898316" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Cross-Reactivity among Beta-Lactams.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15805383" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : A review of evidence supporting the American Academy of Pediatrics recommendation for prescribing cephalosporin antibiotics for penicillin-allergic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29017833" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Cross-reactivity inβ-Lactam Allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28843343" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : The 3 Cs of Antibiotic Allergy-Classification, Cross-Reactivity, and Collaboration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31170539" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Cross-Reactivity to Cephalosporins and Carbapenems in Penicillin-Allergic Patients: Two Systematic Reviews and Meta-Analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29408440" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Cross-Reactivity and Tolerability of Cephalosporins in Patients with IgE-Mediated Hypersensitivity to Penicillins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25609352" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Improving the Effectiveness of Penicillin Allergy De-labeling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10329829" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Natural evolution of skin test sensitivity in patients allergic to beta-lactam antibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24673580" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Natural evolution of skin-test sensitivity in patients with IgE-mediated hypersensitivity to cephalosporins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19133923" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Update on the evaluation of hypersensitivity reactions to betalactams.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14510712" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Diagnosis of immediate allergic reactions to beta-lactam antibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23751142" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Validation of the cephalosporin intradermal skin test for predicting immediate hypersensitivity: a prospective study with drug challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14568857" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Delayed drug hypersensitivity reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30573342" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Controversies in drug allergy: Testing for delayed reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30843233" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Immune pathomechanism and classification of drug hypersensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3535575" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Drug reactions: allergy and near-allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18094951" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : A complex interaction between drug allergy and viral infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9169264" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Cephalexin rash in infectious mononucleosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29617685" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Incidence of Antibiotic-Related Rash in Children with Epstein-Barr Virus Infection and Evaluation of the Frequency of Confirmed Antibiotic Hypersensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27620494" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Antibiotic-Induced Rash in Patients With Infectious Mononucleosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15888154" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : The usefulness of skin tests to prove drug hypersensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22322006" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Diagnosing nonimmediate reactions to cephalosporins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27477905" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Patch testing - a valuable tool for investigating non-immediate cutaneous adverse drug reactions to antibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23136927" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30266590" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : The safety of antibiotic skin testing in severe T-cell-mediated hypersensitivity of immunocompetent and immunocompromised hosts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24565763" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Antibiotic allergies in children and adults: from clinical symptoms to skin testing diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28958742" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : A survey of drug allergy training opportunities in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21293146" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Full-course drug challenge test in the diagnosis of delayed allergic reactions to penicillin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19178402" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Skin testing and drug provocation in the diagnosis of nonimmediate reactions to aminopenicillins in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22464676" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Nonimmediate drug allergy: diagnostic benefit of skin testing and practical approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30431680" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Follow-up of patients with negative drug provocation tests to betalactams.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1421644" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : Cephalexin-induced Stevens-Johnson syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15328988" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : Steven Johnson syndrome due to I.V Ceftriaxone--a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18566552" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : Cephalosporin induced toxic epidermal necrolysis and subsequent penicillin drug exanthem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24599767" id="rid186" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>187 : Severe cutaneous adverse reactions related to systemic antibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16021293" id="rid187" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>188 : Acute generalized exanthematous pustulosis (AGEP). Case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21103192" id="rid188" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>189 : Acute Generalized Exanthematous Pustulosis Induced by Cefepime: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19925632" id="rid189" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>190 : Acute generalized exanthematous pustulosis (AGEP) induced by cefotaxime.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31050838" id="rid190" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>191 : Acute generalized exanthematous pustulosis due to ceftriaxone: Report of a pediatric case with recurrence after positive patch test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31571276" id="rid191" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>192 : Cross-reactivity in beta-lactams after a non-immediate cutaneous adverse reaction: experience of a reference centre for toxic bullous diseases and severe cutaneous adverse reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16540071" id="rid192" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>193 : Patch tests for diagnosis of delayed hypersensitivity to cephalosporins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26375226" id="rid193" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>194 : Acute generalized exanthematous pustulosis x Von Zumbusch's pustular psoriasis: a diagnostic challenge in a psoriatic patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28099605" id="rid194" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>195 : Acute localized exanthematous pustulosis caused by cefoperazone and sodium sulbactam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29266388" id="rid195" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>196 : Localized, ovoid urticarial plaques with fine, nonfollicular pustules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7071457" id="rid196" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>197 : Drug-induced fever: cases seen in the evaluation of unexplained fever in a general hospital population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6311788" id="rid197" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>198 : Alternative antibiotics for the treatment of Pseudomonas infections in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7153193" id="rid198" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>199 : Adverse effects of third-generation cephalosporins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3890658" id="rid199" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>200 : Cefamandole and cefoxitin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16352341" id="rid200" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>201 : DRESS like severe drug rash with eosinophilia, atypic lymphocytosis and fever secondary to ceftriaxone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17578496" id="rid201" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>202 : DRESS syndrome from cefadroxil confirmed by positive patch test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18533962" id="rid202" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>203 : Drug rash with eosinophilia and systemic symptoms induced by cefotaxime and ampicillin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18040726" id="rid203" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>204 : Acute renal failure in a 3-year-old child as part of the drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome following hepatitis A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22511907" id="rid204" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>205 : Drug rash with eosinophilia and systemic symptoms syndrome following cholestatic hepatitis A: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27364942" id="rid205" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>206 : Cefotaxime-induced drug rash with eosinophilia and systemic symptoms syndrome in a 7-year-old boy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28288233" id="rid206" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>207 : [DRESS syndrome in paediatrics: Clinical case].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29629004" id="rid207" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>208 : Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome associated with cefotaxime and clindamycin use in a 6 year-old boy: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27923648" id="rid208" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>209 : Drug reaction with eosinophilia and systemic symptoms from ceftriaxone confirmed by positive patch test: An immunohistochemical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27862184" id="rid209" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>210 : Serum sickness-like drug reaction: two cases with a neutrophilic urticarial pattern.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12041822" id="rid210" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>211 : Serum sickness-like reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7965438" id="rid211" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>212 : Serum sickness-like reactions to cefaclor: role of hepatic metabolism and individual susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9663184" id="rid212" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>213 : Serum sickness-like reaction to cefaclor: lack of in vitro cross-reactivity with loracarbef.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10449953" id="rid213" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>214 : Drug-induced linear IgA bullous dermatosis associated with ceftriaxone- and metronidazole-specific T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18717612" id="rid214" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>215 : Ceftriaxone-induced fixed drug eruption: first report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29047164" id="rid215" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>216 : Multifocal fixed drug eruption to ceftazidime in a child with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29469697" id="rid216" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>217 : Generalized bullous fixed drug eruption imitating toxic epidermal necrolysis: a case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27016799" id="rid217" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>218 : Cross-reactivity and tolerability of aztreonam and cephalosporins in subjects with a T cell-mediated hypersensitivity to penicillins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24180646" id="rid218" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>219 : Absence of cross-reactivity to carbapenems in patients with delayed hypersensitivity to penicillins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11991289" id="rid219" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>220 : General considerations for skin test procedures in the diagnosis of drug hypersensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24740692" id="rid220" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>221 : Skin testing and patch testing in non-IgE-mediated drug allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28293415" id="rid221" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>222 : Approach to the diagnosis of drug hypersensitivity reactions: similarities and differences between Europe and North America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32898711" id="rid222" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>223 : Differentiating Betweenβ-Lactam-Induced Serum Sickness-Like Reactions and Viral Exanthem in Children Using a Graded Oral Challenge.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
